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ABSTRACT 
Background: Infections of the female genital tract are common and have severe impact on 
the quality of life and sexual health of affected women. The innate immune system is crucial 
and is involved in the defense of infections. Understanding innate immunity of the vaginal 
and cervical mucosa is important to enable development of future preventive and therapeutic 
strategies for genital infections. 
Objective: The aim of this thesis was to investigate innate immune factors in women with 
recurrent candida vulvovaginitis (RVVC) and high grade squamous intraepithelial lesions 
(HSIL) of the cervix, induced by human papilloma virus (HPV). This in order to contribute to 
the understanding of the innate immune response in these two common infections of the 
lower female genital tract. 
Material and Methods: Clinical examinations, measurements of intravaginal nitric oxide 
(NO) levels and vaginal biopsies were performed in 28 patients with RVVC and 31 healthy 
controls. Cervical biopsies and vaginal lavage were collected from 19 patients with HPV 
induced HSIL and 14 controls. Immunohistochemistry (IHC), enzyme-linked immunosorbent 
assay (ELISA), western blot and reverse transcriptase real time polymerase chain reaction 
(PCR)) were used to identify and quantify inducible nitric oxide synthase (iNOS), 
antimicrobial proteins, cytokines and encoding genes. Adhesion and binding assays were 
performed to evaluate the adhesive capacity of candida and to demonstrate the binding 
between candida and the antimicrobial protein psoriasin. Transmission electron microscopy 
was conducted to measure the cell wall thickness in C. albicans affected by psoriasin. To 
evaluate a new treatment strategy for RVVC, the effect of chlorhexidine digluconate and 
fluconazole on C. albicans eradication and biofilm was investigated in RVVC and 
commensal strains, using the crystal violet method and viable count. 
Results: NO levels were significantly higher in patients during acute infection compared to 
controls. Levels decreased after fluconazole treatment but remained higher than in controls. 
Furthermore, increased expression of iNOS was observed in the epithelial basal layer in 
patients both before and after treatment. There were positive correlations between NO levels, 
clinical symptoms and examination scores. Findings indicated that C. albicans induces 
production of psoriasin during mucosal candida infection. Psoriasin was shown to interact 
with β-glucan in the candida cell wall and inhibit candida adhesion to surfaces. In HPV 
induced HSIL, psoriasin expression and protein levels increased significantly after surgical 
treatment and reached similar levels as in controls. The mRNA expression of the pro-
inflammatory cytokine IL-8 was higher before treatment and restored to the same levels as in 
controls six months after lesions were excised. Chlorhexidine digluconate prevented new 
biofilm formation and reduced already established C. albicans biofilm. Moreover, the number 
of candida cells in both planktonic state and within the biofilm were significantly decreased. 
Although fluconazole reduced the growth of C. albicans, no effect was observed on biofilm 
or candida cells in the biofilm. 
Conclusions: Several factors of the innate immune system are involved in the local immune 
response to RVVC and cervical HPV induced HSIL. The mucosal inflammation during an 
acute episode of RVVC is well demonstrated by the pronounced increase of vaginal NO, also 
corresponding to intensity of symptoms. The AMP psoriasin was upregulated in RVVC and 
was found to have an anti-adhesive effect on C. albicans, a result contributing to the 
understanding of host-pathogen interaction during candida infections. Although fluconazole 
is the first line treatment of RVVC, the effect is not always satisfactory. According to our 
results, one explanation could be an inability of fluconazole to dissolve biofilm and eliminate 
candida cells within the biofilm. Instead local application of chlorhexidine digluconate might 
be an alternative prophylactic and treatment strategy that inhibits biofilm formation and 
eradicates C. albicans both in planktonic phase and within biofilm. Alterations in expression 
of antimicrobial peptides and pro-inflammatory markers in HPV induced cervical HSIL 
demonstrate activation of innate immunity also in premalignant lesions, however the 
importance of these results needs further exploration. 
 
Keywords: C. albicans, recurrent vulvovaginal candidiasis (RVVC), nitric oxide (NO), 
inducible nitric oxide synthase, (iNOS), antimicrobial peptides (AMP), psoriasin, β-glucan, 
cervical dysplasia, high-grade squamous intraepithelial lesions (HSIL), human papilloma 
virus (HPV), biofilm, chlorhexidine digluconate (CHG) 
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1 INTRODUCTION 
1.1 INFECTIONS IN THE LOWER FEMALE GENITAL TRACT 
Infections of the female genital tract are common and cause a large proportion of visits to 
gynecological clinics worldwide. The infections have a severe impact on the sexual health 
and quality of life in the affected women and leads to significant health care costs [1]. 
Several different types of bacteria, virus, fungi and parasites infect the female genital tract 
(FGT). Infections can be recurrent or persistent and cause long-term suffering. Common 
pathogens include Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, 
Mycoplasma genitalium, Gardnerella vaginalis, Mycoplasma hominis, human papilloma 
virus (HPV), herpes simplex virus (HSV), human immunodeficiency virus (HIV), candida 
species and Trichomonas vaginalis.  
The main site of infection varies due to differing susceptibility of the infecting 
microorganisms in various regions of the FGT. Candida albicans and Trichomonas vaginalis 
colonize the vagina whereas the endocervix and transformation zone of the cervix is 
vulnerable to infection by Chlamydia trachomatis, Neisseria gonorrhea, Mycoplasma 
genitalum and oncogenic strains of HPV [2-6]. Vaginitis is caused by infection and 
inflammation of the vaginal mucosa. In cervicitis the infection affects the cervical mucosa, 
mainly the columnar epithelial cells, but it may also cause visible changes to the ectocervix 
whose squamous epithelium is continuous with the vaginal epithelium. Vulvitis is an 
infection or inflammation of the vulvar skin and mucosa [7]. 
Symptoms of infections differ but there are several similarities. The most common symptoms 
are excessive vaginal discharge, erythema, pruritus, pain, dyspareunia, discomfort during 
urination and mild bleeding. Most infections, but not all, are sexually transmitted and there is 
a clear association between bacterial vaginosis (BV) and an increased risk of incurring 
infections such as HIV and HSV-2 [8]. 
This thesis focus on factors of the innate immune defense during recurrent vulvovaginal 
candidiasis and HPV induced cervical intraepithelial lesions (CIN). These infections have 
major differences in their clinical features and consequences. Candida causes numerous local 
symptoms with severe inflammation of the infected tissue [9], while HPV mostly is a quiet, 
non-symptomatic infection but with a potential to induce malignant transformation of the 
affected tissue [10].  
1.1.1 Vulvovaginal candidiasis 
Candida is a commensal yeast organism present in the vaginal flora of about 20% of 
asymptomatic healthy women during their reproductive years [9, 11]. The lifetime incidence 
of sporadic vulvovaginal candidiasis (VVC) is estimated to 75% and 40-50% of women will 
experience recurrence [11, 12]. The rate of infections decreases after menopause. Most 
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women who suffer from sporadic infections are healthy without well-known risk factors such 
as pregnancy, use of antibiotics, diabetes mellitus and immune deficiency.  
Clinical manifestations are pruritus, vaginal discharge, soreness, dysuria and dyspareunia. On 
clinical examination there are prominent signs of inflammation with erythema and edema in 
the vulvovaginal mucosa and an adherent off-white discharge [13]. These symptoms and 
signs are non-specific and diagnosis of VVC needs further verification. Vaginal pH is not 
affected by VVC and the finding of pH ≤ 4.5 helps to exclude bacterial vaginosis (BV). 
Direct microscopic examination of vaginal secretions is an important diagnostic tool. A wet 
mount with saline can identify the presence of yeast cells or hyphae/pseudohyphae and rule 
out the presence of motile trichomonads and clue cells revealing BV. A 10% potassium 
hydroxide preparation might help to identify fungal elements. However, microscopy has a 
sensitivity of 50% at the best [14] and therefore additional vaginal yeast culture is 
recommended in women with symptoms and normal pH and negative microscopy [14]. 
1.1.1.1 Recurrent vulvovaginal candidiasis 
Recurrent vulvovaginal candidiasis (RVVC) is defined as VVC in excess of 3-4 times per 
year [15, 16] and occurs in in 6-9% of premenopausal women [16, 17]. Little is known about 
risk factors and mechanisms leading to relapses in otherwise healthy women. However, the 
causation is likely multifactorial and factors such as contraceptives, sexual behavior, candida 
virulence, genetic factors and chronic stress have been reported [16, 18-21]. A combination 
of ineffective local immune response and specific virulence factors of pathogenic candida 
might be contributing factors. It has been proposed that certain candida strains may persist, 
providing a reservoir for relapsing infections [22-24]. Patients with RVVC exhibit normal 
systemic cell-mediated immune responses to candida [25-27]. However, impaired or changed 
vaginal innate immune response predisposing to RVVC has been proposed [11, 26]. In most 
patients with RVVC no triggering factor is identified.  
Symptoms of RVVC are mainly the same as in VVC with soreness, pruritus and dyspareunia. 
However, the clinical findings may differ and signs of vulvitis often dominate with dry skin, 
excoriations and fissures. These more or less chronic symptoms severely affect the patients’ 
sexual health and quality of life [1, 9]. The repeated inflammatory tissue response might be a 
trigger for chronic vulvar pain conditions developing over time [28, 29]. A vaginal culture is 
important to obtain a correct diagnosis in these patients. If the initial tests are negative, it can 
be helpful to provide patients with culture swabs with transport medium for self-sampling at 
home during a symptomatic relapse. 
1.1.1.2 Candida species 
C. albicans is the most common pathogen in women with VVC (70 to 95%), followed by C. 
glabrata (7 to 16%) [11, 12]. Other species causing VVC are C. parapsilosis, C. tropicalis, 
C. krusei and Saccharomyces cerevisiae. VVC caused by non albicans species are clinically 
impossible to differentiate from VVC caused by C. albicans but are often more difficult to 
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treat. C. albicans has the unique ability to evolve through germination into a more invasive 
mycelial form. This form is capable of invading mucous membranes, possibly explaining its 
predominant role in the pathogenesis of VVC [30]. 
In RVVC, C. albicans is the major causative agent but there are reports that recurrent 
infections caused by non albicans species are increasing, most commonly C. glabrata [16]. 
1.1.1.3 Candida albicans  
C. albicans is a commensal fungus colonizing cutaneous and mucosal surfaces of healthy 
individuals. The colonization increases during antibiotic treatment due to the antibacterial 
effect and reduction of the vaginal bacterial flora. However, C. albicans can cause diseases in 
mucosal membranes such as oral and esophageal candidiasis, vulvovaginal candidiasis and 
skin infections. Immunocompromised patients constitute the highest risk group for severe 
fungal infections [31]. Moreover, indwelling catheters are risk factors due to the ability of the 
fungus to adhere and form biofilm to foreign surfaces [32]. C. albicans can penetrate mucosal 
barriers and endothelia and cause candidemia which can develop to disseminated candidiasis 
when the infection spreads to internal organs [33]. In patients with invasive candidiasis or 
candidemia the mortality is as high as 40-50%, despite adequate antifungal therapy [31, 33]. 
C. albicans has the ability to grow as either unicellular yeast cells or as filamentous 
pseudohyphal or true hyphal forms, Figure 1. Pseudohyphae develops when daughter-buds 
elongates from the yeast cell. The pseudohyphae are distinguishable from hyphae by their 
constrictions at the site of septation and that they are wider than hyphae. True hyphae form 
long tube-like filaments with parallel sides without constrictions [34]. Hyphal form has a key 
role in the infection process by invading epithelial and endothelial cells and is considered to 
be an important virulence factor of C. albicans [33], Figure 2. Yeast blastospores is the 
phenotypic form responsible for transmission from the lower gastrointestinal tract and 
asymptomatic colonization of the vagina [16]. 
 
Figure 1. Morphology of C. albicans. Reprinted by permission from Macmillan Publishers Ltd: 
Nature Reviews Microbiology [33], copyright (2011). 
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The candida cell wall is constituted by polysaccharides, glycoproteins, enzymes and lipids. 
The polysaccharides mannan, glucan and chitin are major components of the outer cell wall 
[35], Figure 3. These carbohydrate-containing molecules are recognized by pattern-
recognition receptors (PRR) and the innate immune system activates inflammatory responses 
such as initiation of microbicidal processes by leukocytes, production of reactive oxygen 
intermediates, inflammatory mediators and cytokines, including tumor necrosis factor α. 
(TNF-α). The glucans of the candida cell wall are recognized by cells of the innate immune 
system and are important fungal pathogen associated molecular patterns (PAMPS) [35]. 
Binding of  β-glucan to the C-type lectin dectin-1 receptor, a PPR that mediates induction of 
pro-inflammatory cytokines in intestinal epithelial cells [36] and keratinocytes [37]. The 
Dectin-1 receptor also interacts with other PRRs to promote signals inducing immune 
responses such as production of cytokines and reactive oxygen species (ROS) [38, 39]. 
Moreover, the size and physical properties of the molecules regulate the immune response 
where large β-glucan particles stimulate cytokine and ROS production and phagocytosis, 
while soluble β-glucans bind to but do not activate the Dectin-1 receptor [38, 40, 41]. 
 
Figure 3. Candida albicans yeast cell wall. Reprinted by permission from Macmillan Publishers Ltd: 
Nature Immunology [39], copyright (2012). 
Figure 2. Candida hyphae 
penetrating the epithelium.  
Foto: Eva Rylander  
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1.1.1.4 Treatment 
Most of the available antifungal agents are not fungicidal. Azoles are fungistatic, 
thus inhibiting the growth of fungi leading to a clearance of the infection. Most C. albicans 
strains are susceptible to available antimycotic drugs and real resistance of isolates is rare 
[42-45]. Topical azole agents are available in a variety of formulations and are often sold over 
the counter for self-treatment. For patients with sporadic VVC, topical treatment will have a 
curative effect in 80-90% of cases [23]. Oral systemic azole agents achieve comparable 
therapeutic cure rates in patients with VVC at short term. However, at long-term follow up 
the oral treatment is more effective in achieving mycological cure [46]. A mild vulvovaginal 
burning sensation is a common side effect of topical azoles [23, 47]. Using oral 
administration, local side effects are avoided but instead systemic adverse effects like 
headache, nausea and abdominal pain might occur in rare cases [23, 43, 47]. The oral azoles 
are contraindicated during pregnancy. Less frequently used, but still available treatment 
options are vaginal application of boric-acid, gentian violet and nystatin. They are of no 
advantages in treatment of trivial C .albicans infections but can be useful supplements in 
complicated cases [16]. 
For RVVC caused by C. albicans long-term treatment with fluconazole is recommended. The 
most effective regime to date starts with induction of fluconazole 150 mg every 72 hours for 
3 doses followed by fluconazole 150 mg once weekly for 6 months [16, 43]. Fluconazole has 
a half-life time of 25-hours. After administration of a single dose of oral fluconazole 150 mg, 
concentrations of fluconazole above the minimal inhibitory concentration (MIC) that inhibits 
the growth of 90 % of candida species isolates (MIC 90) are achieved in vaginal tissue and 
secretions for 72-96 hours. Due to the pharmacodynamics, weekly administration is adequate 
[43, 48]. In most cases, there are only a few breakthrough episodes of symptomatic vaginitis 
during the 6 months’ treatment. After cessation of the treatment, 50% of the patients develop 
a new culture positive outbreak of RVVC within 3-4 months. The cultures usually show the 
same strain of candida as before treatment and the strain remains sensitive to fluconazole 
[16]. In those cases, it has been suggested that the azole fails to achieve total eradication of 
candida organisms. When recurrences occur, a new long-term maintenance treatment with 
weekly 150 mg fluconazole for further 6-12 months is recommended [16]. However, in some 
cases it has been reported that long-term usage of antifungals is associated with decreasing 
sensitivity to fluconazole [49]. Itraconazole can be used as an alternative but has a potential 
for liver toxicity and is therefore not a first line choice [16]. 
RVVC with non-albicans candida species are often more complicated to treat due to 
fluconazole resistance. However, C. tropicalis and C. parapsilosis are sensitive to 
fluconazole and can be treated like C. albicans. C. krusei and Saccharomyces cerevisiae are 
resistant to fluconazole and treatment with clotrimazole, boric acid or nystatin is needed [12]. 
Also approximately 50% of C. glabrata strains are resistant to fluconazole and therefore local 
treatment with clotrimazole or boric acid is recommended 
Patients with RVVC need to avoid dehydration of the mucosal tissue by limiting the use of 
soap and water. Oil and emollient regime is recommended. Probiotics with exogenous 
lactobacillus species have been suggested to prevent RVVC, however, there are few studies 
on the efficacy and the results are inconclusive [16, 50]. Although partners often harbor 
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strains of candida in saliva, rectum or semen it is not proven to be associated with 
recurrences. Partner treatment is therefore not recommended [51, 52]. 
Curative treatment for RVVC is difficult to obtain and many patients have symptoms 
affecting their quality of life for many years. New antifungal strategies are therefore of great 
importance for both treatment and prevention of these relapsing infections. 
 
1.1.2 Biofilm formation and persister cells 
Biofilm is a survival mechanism used by several microorganisms and can be formed on both 
biotic and abiotic surfaces [53] such as vaginal epithelial cells [54] and intrauterine devices 
[55, 56]. They are considered to contribute to approximately 80% of microbial infections in 
the human body [57] and the formation on medical devices such as catheters and heart valves 
are a major factor causing candidemia with high mortality rate [58, 59]. The biofilm of C. 
albicans is a complex and robust three-dimensional structure containing an exopolymer 
matrix and a mixture of yeast, pseudohyphae and hyphae [60] Figure 4. The biofilm shields 
candida from the immune system and antifungal treatment [61, 62]. Formation of biofilm is 
induced when C. albicans adhere to the epithelial cells with help of the mannoproteins and 
adhesins of the fungal cell surface. After adherence, the initiation of micro colonies starts and 
subsequently the maturation of the biofilm occurs by the production of extracellular 
polymeric substances and increase of cell numbers. The candida biofilm extracellular matrix 
is composed of polysaccharides, proteins, phosphorus and uronic acid which scaffolds the 
biofilm integrity [60, 63]. Although the biofilm is an effective way for microorganisms to 
circumvent eradication, it does not completely hinder penetration of antifungal treatment. 
Genes and metabolic pathways might be downregulated in some cells of the biofilm [64, 65].  
Many cells in the biofilm are killed by antifungal treatment but a small subpopulation of 
highly drug tolerant dormant persister cells can survive [62, 66]. On cessation of 
antimicrobial treatment, the persister cells are dispersed and repopulate the biofilm or 
colonize new surfaces thereby causing relapse of the infection. However, when these cells are 
detached from the biofilm they are susceptible to treatment, indicating that persister 
mechanisms are due to phenotypic changes and not genetic mutations [59, 67]. Persistence is 
thereby distinct from resistance were the microbes becomes resistant to the given 
treatment.[68].  
Persister cells are acknowledged to play a major role in the recalcitrant nature of chronic 
infections such as cystic fibrosis pneumonia caused by Pseudomonas aeruginosa, 
tuberculosis caused by Mycobacterium tuberculosis and oral candidiasis caused by Candida 
albicans [67]. 
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Figure 4. Biofilm formation and persister cells. Reprinted by permission from Springer Nature: 
Nature Reviews Microbiology [65], copyright (2017). 
 
1.1.3 HPV 
Human papilloma virus (HPV) are double stranded DNA viruses that infect epithelial cells. A 
subgroup of which have been proven to be etiologically involved in the development of 
human cancer. More than 200 types of human papilloma viruses are identified [69]. HPV 
infection is globally the most widespread sexually transmitted infection (STI) and most 
sexually active individuals are likely to be exposed during their lifetime [70]. The viruses 
have predilection for cutaneous and mucosal epithelial tissues. They are divided into groups 
of low-risk and high-risk HPV depending on their potential to induce carcinogenesis. HPV 
infect basal cells of stratified squamous epithelium, which can be reached as a result of 
micro-abrasions and wounds [69]. HPV are intracellular pathogens dependent of the cell 
machinery of the basal cells in the epithelium to replicate and the HPV DNA becomes 
incorporated in the host cell DNA [70] . Most infected individuals will effectively eliminate 
the virus. However, likely due to immune evasion approximately 15% of infections will 
become persistent. Several possible mechanisms explaining immune evasion have been 
described [10, 71]. During differentiation, the virus replicates inside the cells and is therefore 
practically invisible to the host immune system. Virus shedding occurs in the upper layers of 
the epithelium without causing tissue damage or viremia [10, 70]. Furthermore, HPV 
downregulates the expression of interferon genes. Interferons are cytokines with potent anti-
viral and immunostimulatory effects. [10, 70, 71]. Despite these immune avoiding capacities, 
a majority of HPV infections resolve with time, mainly thanks to cell mediated immune 
response [72].  
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1.1.3.1 HPV infections and related diseases 
HPVs show a high grade of tissue tropism and various types of HPV infect particular 
anatomic areas. The low-risk viruses cause benign hyper-proliferative lesions such as warts 
among which HPV 6 and 11 cause condyloma acuminatum in the anogenital area [5]. 
Whereas infections with high risk HPVs can cause invisible or asymptomatic precursor 
lesions, with the ability to advance to premalignant lesions and invasive cancer and are a 
major cause of cancers of the cervix, vagina, vulva, anus, penis and oropharynx [73].  
Worldwide, cervical cancer is the third most common female cancer with approximately 85% 
occurring in less developed regions [73]. Nearly 100% of all cervical cancer patients are HPV 
positive and HPV 16 and 18 are responsible for approximately 70% of cervical carcinomas 
[70, 72]. Lately, the incidence of HPV positive oropharyngeal squamous cell carcinomas 
(OPSCC) has increased [74]. It has been speculated that the reason for this development 
might be alterations in sexual habits with a significant association between HPV-positive 
OPSCC, early sex debut and number of partners engaged in oral or vaginal sex. Eighty-eight 
percent of anal cancers are HPV related and populations at increased risk are HIV-positive 
patients and men having sex with men [75]. 
1.1.3.2 Cervical HPV lesions 
The ectocervix constitutes of stratified squamous epithelium and the endocervix, with the 
endocervical canal, is lined by a single layer of columnar epithelium. The squamocolumnar 
junction (SCJ) is the area where these two cell types converge. The transformation zone (TZ) 
is the area of squamous metaplasia between the current and original squamocolumnar 
junction. The TZ is characterized by immature squamous epithelium. The proliferating cells 
of the metaplastic epithelium are susceptible to HPV infection and TZ is where high-risk 
HPV-associated lesions primarily develop [5, 69]. 
Of all HPV positive women, approximately 15% develop a persistent infection of the cervical 
epithelium [76]. Persistent HPV infections may slowly progress to cervical low- and high-
grade squamous intraepithelial lesions (LSIL, HSIL) with the potential to develop to invasive 
squamous cell carcinoma (SCC) [77], Figure 5. Cofactors increasing the risk of progression 
are a compromised immune system and other co-infections such as HSV 2, Chlamydia 
trachomatis, Neisseria gonorrhoeae and BV [76, 78, 79]. Prolonged use of oral 
contraceptives (OC), high parity and smoking are other risk factors for persistent infection 
[80]. Invasive cancer may develop over several years in a minority of women with HSIL. In 
Sweden the median age of acquired cervical cancer is 50 years, with an interval ranging from 
20 to 85 years [81].  
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Figure 5. Development of cervical intraepithelial neoplasia. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Cancer [77], copyright (2007). 
 
1.1.3.3 Screening and diagnosing 
Since the early 1960s a national screening program has been in place in Sweden, initially 
using Pap smears to detect precancerous cervical lesions. The method was described by Dr. 
Papanicolaou in the early 1940s. Despite a low sensitivity of only approximately 55% to 
detect a high grade dysplasia (CIN2+) by a single Pap smear (ranged 30- 80%) [82, 83], the 
screening program has been successful in reducing the incidence and mortality of cervical 
cancer by 35-70%. In fact, 64% of all cervical cancers and 83% of advanced cases in Sweden 
were diagnosed in women not attending the screening program [84]. Recently liquid-based 
cytology (LBC) has largely replaced the Pap smear as sampling method. The cells are 
collected similarly as for the Pap smear, but instead of primarily distributing the cells on a 
glass slide, the cells are immersed and rinsed in a collection fluid before fixation and staining. 
This reduces the number of inadequate samples by eliminating aggravating factors such as 
blood, mucus and cell deposits and provides an optimal thin layer of cells beneficial for 
microscopic interpretation. The LBC also enables supplementary testing of high-risk HPV 
DNA or RNA, increasing the sensitivity for detecting HSIL compared to cytology alone [85]. 
In the new national Swedish guidelines, HPV analysis is recommended as primary screening 
method followed by cytology in women older than 30 years [86, 87].  
1.1.3.4 Treatment 
When primary screening show signs of atypia the patients are referred for colposcopy and 
biopsy of the TZ or any visible lesion. Treatment is recommended when HSIL is detected or 
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when the colposcopy is incomplete [86]. The aim of treatment is to excise the high-grade 
lesion with minimum harm to the cervix. Excision methods used are loop electrosurgical 
excision procedure (LEEP) or laser conisation and previously cold knife cone biopsy. 
Excisional treatments are effective and cause low morbidity [88]. For persistent lower grade 
lesions, destruction by laser ablation or cryotherapy might be an option. 
1.1.3.5 HPV Vaccines 
A dramatic breakthrough in combating HPV infections was the introduction of HPV virus-
like particle (VPL) vaccines. Administered by intramuscular injection the vaccine has a rapid 
access to local lymph nodes and induce a potent antibody response, with antibody 
concentrations up to 40 times higher than after a natural infection [89]. The vaccines are well 
tolerated and effective with almost 100% seroconversion [90]. In addition, available vaccines 
have shown cross-protection against non-vaccine HPV strands.[91, 92]. In Sweden, HPV 
vaccination for girls has been included in the national vaccination program since 2010. The 
vaccine has also been shown to protect adult women from infections and lesions caused by 
the vaccine type HPVs. Including boys would protect against HPV related cancers and genital 
warts in men and have beneficial effects for protection of non-vaccinated women and males 
through increased herd immunity [91]. 
  
1.2 THE IMMUNE DEFENSE OF THE FEMALE GENITAL TRACT 
The female reproductive tract requires an exceptional regulation of the immune defense. In 
addition to protection against infectious microbes it must also adjust to a wide range of 
physiological events including fertilization by allogenic spermatozoa, implantation, 
pregnancy with an immunologically distinct fetus and parturition. The mucosal system is 
under hormonal control throughout the menstrual cycle. Protection against potential 
pathogens in the FRT is provided by a range of activities that can be grouped into two 
categories, the innate and adaptive immune defense.   
 
1.2.1 Laktobacillus 
Lactobacillus spp dominates the vaginal flora in approximately 70% of premenopausal 
women. The most commonly isolated species are L. crispatus, L. gasseri, L. jensenii and L. 
iners [93]. The lactobacillus dominated microbiota is important for a healthy vaginal 
ecosystem. The metabolic products lactic acid, hydrogen peroxide (H2O2) and bacteriocins 
are secreted in the cervicovaginal fluid and can directly eradicate or inhibit harmful 
pathogens. By formation of microcolonies and biofilm that adhere to the epithelial cells, a 
physical barrier against pathogen adhesion is produced. A low vaginal pH of ≤ 4.5 is one of 
the main inhibitory mechanism for preventing pathogen colonization of the vaginal tract [94]. 
This is supported by the fact that risk of STIs acquisition is increased in patients with BV 
[93]. 
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1.2.2 Innate immune defense 
Innate immunity is present even in the in most primitive multicellular organisms. It is an 
ancient form of immune defense that has evolved by natural selection over millions of years. 
Genes encoding for these innate immune molecules are inherited from one generation to the 
next in a stable form. The innate immune system is considered the first line defense and 
efficiently clear most pathogenic microorganisms. Without a functioning innate immune 
system we are extremely susceptible to infections.  
1.2.2.1 Epithelial cells- the barrier protection 
The mucosal lining of the female genital tract, composed by mucus and epithelial cells, 
provides a physical and immunological barrier to pathogens. The epithelial cells produce 
mucus, antimicrobial peptides, chemokines and cytokines [95-97]. The cervix, the uterus and 
the fallopian tubes are lined with columnar epithelium as opposed to vaginal mucosa which 
consists of a multilayered non keratinized stratified squamous epithelium. The epithelium 
undergoes differentiation and contains several distinct layers. Exfoliation is an effective way 
to eliminate pathogens attached to the vaginal mucosa. The epithelial cells contain large 
cytoplasmic stores of glycogen [98]. Glycogen is a major component of exfoliated cells and 
serve as a substrate for lactobacilli that produce lactic acid and thereby maintain an acidic pH 
[99]. Sex hormones influence the thickness of the vaginal epithelium and the glycogen 
content of the cells. After menopause, with low levels of endogenous estrogen, the vaginal 
epithelium becomes thinner and glycogen stores are diminished [100, 101]. The physical 
barrier formed by epithelial cells is dependent on the presence of tight junctions between the 
cells. In the apical layers of the vaginal and ectocervical epithelia, there is a lack of tight 
junctions allowing intraepithelial transport of pathogens and immune cells in the spaces 
between the cells [98, 102, 103]. The epithelial cells express pattern recognition receptors 
(PRRs), such as Toll like receptors (TLRs) and C-type lectin receptors (CLR) which 
recognize pathogen associated molecular patterns (PAMPs) on microorganisms. When the 
PRRs are stimulated by PAMP the epithelial cells respond with secretion of antimicrobial 
peptides (AMP), cytokines and chemokines. 
1.2.2.2 Complement 
When a pathogen penetrates the epithelial barrier the complement system is activated. It is a 
system of soluble proteins constitutively produced by the liver and are present in blood, 
lymph, extracellular fluids and in vaginal secretions. Complement proteins attach to the 
surface of bacteria and extracellular virus and make them susceptible for phagocytosis. The 
complement system consists of more than 30 components [104].  
1.2.2.3 Innate immune cells 
Circulating monocytes are effector cells in both the innate and the adaptive immune defense. 
They migrate into tissues where they differentiate into macrophages. Macrophages are long 
lived phagocytic cells and play a major part in the initiation, maintenance and resolution of 
 12 
the inflammatory response. Approximately 10% of the leukocytes present in the FRT are 
macrophages, with high amounts in the endometrial stroma and myometrial connective tissue 
[102, 105]. The number of macrophages in the endometrial tissue is regulated by estradiol 
and progesterone levels but in vaginal tissue the numbers of macrophages remain stable 
throughout the menstrual cycle [102, 105]. Macrophages and dendritic cells are antigen 
presenting cells. Pathogen exposure and phagocytosis induce antigen presentation, generating 
responses of the adaptive immune system [104]. 
Natural killer cells (NK-cells) are the killer lymphocytes of the innate immune defense and 
provide an early defense against intracellular infections. NK-cells possess cytotoxic activity, 
produce and secrete cytokines and have the ability to kill tumor cells. Their important role in 
the FRT innate defense is observed by the increased rate of HSV infections and an increased 
incidence of cancer in patients with malfunctioning NK cell [102, 105]. 
Neutrophils circulate in the bloodstream and are attracted to sites of infection by 
inflammatory mediators. There they interact with the walls of the capillaries, leave the blood 
stream and move in to the infected area in large numbers. Neutrophils are also present in all 
tissues of the FRT under healthy conditions and the amount of neutrophils in vaginal tissue is 
constant during the menstrual cycle [100]. When vaginal candida infection was 
experimentally induced in healthy women, there was a neutrophil tissue infiltration and 
inflammation in the symptomatic cases as opposed to asymptomatic cases. This suggests that 
neutrophils are important for the immuno-pathogenesis and symptomatology of the infectious 
process [106]. 
1.2.2.4 Cytokines and Chemokines 
Cytokines are small proteins that are produced by immune and epithelial cells and regulate 
immunity, inflammation and hematopoiesis. They stimulate a potent innate immune response, 
which create a hostile environment for pathogens and are regulators of the adaptive immune 
system. They have powerful inflammatory effects localized to the infected tissue and the 
effects can also be expressed systemically throughout the body. Secretion of cytokines and 
chemokines lead to interactions between the different cell categories in the FRT. The 
cytokine levels of cervico-vaginal fluid change during the menstrual cycle and gestation [107, 
108]. 
In response to infection, proinflammatory cytokines, including tumor necrosis factor (TNF), 
interleukins IL-1, IL-6, IL12 and IL-8 are produced, but once the stimulus is eliminated the 
inflammatory reaction is naturally controlled and tissue repair is induced [109]. The 
resolution of inflammation is regulated by several anti-inflammatory mediators like IL4, IL 
10, IL-13 and transforming growth factor (TGF)-β [110]. By clearance of dying cells by 
phagocytes the tissue damage is repaired [111]. 
Chemokines such as IL-8, produced by cells on the site of infection, are chemoattractants that 
recruit neutrophils to eradicate microorganisms. They are also involved in cell proliferation, 
differentiation and angiogenesis [112, 113] . 
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1.2.2.5 Nitric oxide 
The Nobel Prize in Physiology or Medicine 1998 awarded Furchgott, Murad and Ignarro for 
their discoveries concerning nitric oxide (NO) as a signaling molecule. This was the first 
discovery that a gas can act as a signal molecule in an organism.  
NO is a short lived biologically active free radical gas having an elimination half-life of only 
a few seconds. The molecule is present in biological tissues and is an active substance 
involved in numerous physiological processes such as relaxation of smooth muscle cells, 
neurotransmission, vascular hemostasis and is part of the nonspecific host defense [114]. It 
has cytotoxic effects against microorganisms and tumor cells [115]. NO is synthesized in vivo 
through the conversion of the amninoacid L-arginin to L-citruline by a process catalyzed by 
enzymes known as nitric oxide synthases (NOS). The enzymatic reaction require 
Nicotinamide adenine dinucleotide phosphate (NADPH) as co-substrate and Heme, Flavin 
mononucleotide (FMN), Flavin adenine dinucleotide (FAD), Tetrahydrobiopterin (BH4) and 
Calmodulin (CaM) as cofactors [116], Figure 6.  
 
 
Figure 6. The synthesis of NO. 
 
Three forms of NOS have been described, neuronal NOS (nNOS), endothelial NOS (eNOS) 
and inducible NOS (iNOS).  nNOS and eNOS are named after the tissue in which they first 
were found. They are constitutively expressed and are calcium dependent. iNOs was 
originally identified as being inducible by cytokines in macrophages and hepatocytes and is 
calcium independent [116]. It is widely expressed in various cell types and is induced by 
bacterial lipopolysaccharides (LPS) and proinflammatory cytokines [117, 118]. 
Nitric oxide has several significant roles in inflammation. It is a potent vasodilator and plays 
an essential role in vascular function during the inflammatory process. NO reduces platelet 
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aggregation and adhesion and acts as a regulator of leukocyte recruitment. It has anti-
microbial activity by limiting replication of bacteria, protozoa, fungi and viruses and it has 
been shown that NO is bactericidal to various strains of bacteria [119, 120]. However, NO 
can also induce cytotoxic effects in tissues by oxidative injury with cellular and organ 
dysfunction due to its interaction with oxygen radicals generating peroxynitrite [121]. The 
role of NO in HIV infection is dichotomous since NO seems to have double functions in the 
pathogenesis of HIV-1 by both blocking HIV-1 replication and by the NO-induced oxidative 
stress leading to rapid viral evolution [121]. 
NO measurement in biological specimen is difficult due to the lability of NO in the presence 
of oxygen. There are assays that indirectly reveal the presence of NO by measuring NO 
metabolites. However, chemiluminescence is a direct method for NO measurement in the gas 
phase. It is based on the interaction of ozone and NO that generates light. A sample 
containing gaseous NO is mixed with ozone and the emitting light is measured by a 
photodetector. The amount of light is proportional to NO levels in the sample [122]. 
Increased NO formation has been shown in numerous inflammatory conditions such as 
asthma, colitis, cystitis, rheumatoid arthritis and pelvic inflammatory disease [123-130]. In 
patients with asthma, NO levels in orally exhaled air have shown a 2-10 fold increase 
compared to healthy controls and the levels correlate with disease severity. Glucocorticoid 
treatment of inflammation are known to inhibit iNOS and treatment with inhaled or oral 
glucocorticoids reduces NO levels in asthma patients in a dose-dependent way [131, 132]. 
Using NO values to prescribe a patient’s daily dose of inhaled corticosteroids enabled 
reduction in the total dose of corticosteroid required, compared with traditional spirometry 
and symptom based approaches and has been suggested as a quick and non-interventional 
method with high patient acceptability [124, 133]. In patients with interstitial cystitis there is 
a significant correlation between symptoms and changes in NO concentration [134]. This 
implies that NO measurement can be used for diagnosing and monitoring the grade of 
inflammation in affected organs and to evaluate the treatment response in patients with 
various inflammatory diseases [124, 134] 
However, NO may cause local and systemic tissue damage and thereby contribute to the 
morbidity of infections. The exact role in vivo is yet to be clarified and the beneficial and 
harmful effects of NO need further elucidation. 
1.2.2.6 Antimicrobial peptides 
Antimicrobial peptides are important effector molecules of the innate immune system and are 
present in all kinds of living organisms. They are defined as peptides that contain fewer than 
100 amino acids and exhibit broad-spectrum antimicrobial activity against bacteria, fungi and 
enveloped viruses. Nearly all AMPs are cationic and hydrophobic and exert their 
antimicrobial action by disrupting bacterial, fungal or viral membranes [135]. By electrostatic 
interaction between the negatively charged microbial membranes and the cationic peptides 
with hydrophobic properties, the peptide is inserted to the membrane leading to disruption 
and lysis of the microbe [136-138]. AMPs interact with both the innate and the adaptive 
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immune systems [139, 140] and can interfere with adhesion of microorganisms and with 
biofilm formation [141, 142]. In fungus, the membrane is electronically neutral and AMPs 
seem to target the polysaccharides and surface receptors in the fungal cell wall [143, 144]. 
Against viruses the AMPs use a wide variety of antimicrobial activities. In enveloped viruses, 
such as HSV, AMPs target the surface antigen that mediate attachment and fusion with host 
cells. In the non-enveloped viruses, such as HPV, the target of AMPs is the viral cell entry, 
un-coating or replication processes [145, 146]. 
Several families of AMPs have been identified in humans. Major groups are the defensins, 
cathelicidin and S100 proteins. Defensins are 2- to 6-kDa peptides with six cysteines and 
three disulfide bridges. The size and the organization of the disulfide bridges further divides 
the defensins into two major subgroups: α-defensins and β-defensins. The α-defensins are 
present in phagocytic cells such as neutrophils and in the paneth cells of the small intestine 
[147, 148]. They are stored in the granules of neutrophils and contribute to the elimination of 
ingested microbes [149]. The α-defensin 5 (HD5) is present in the FRT and has been shown 
to have a potent antiviral activity especially against HPV infections [150]. However, HD5 
seems to be almost absent in the TZ of women with cervical HSIL [151]. The β-defensins are 
present in epithelial and phagocytic cells and are expressed in a variety of tissues including 
the FRT [152, 153].  Human β-defensin -1 (HBD-1) is constitutively expressed but may also 
be selectively upregulated whereas HBD -2 -3 and -4 are induced by infectious and 
inflammatory stimuli [154-156]. LL-37 is the only human cathelicidin and it is expressed in 
neutrophils and numerous epithelial tissues such as the urinary tract, skin, lung and 
epididymis [157-161]. Cathelicidin has been demonstrated to have antimicrobial activity 
against a wide range of pathogens as well as potent chemotactic activity. Moreover, it has 
been shown to be involved in carcinogenesis and progression in tumors of the breast, ovaries 
and lungs as well as head and neck squamous cell carcinoma [162]. It is also involved in 
tissue repair by angiogenesis [163].  
The S100 family of proteins consists of several Ca 2+ binding proteins. Psoriasin (S100A7) is 
an AMP that belongs to this group. It is a monomeric peptide composed of 101 amino acids, 
normally existing as a homodimer composed of two monomers [164]. The binding motifs of 
calcium and zinc are important parts of the peptide and binding of calcium is crucial for the 
structure development of the protein [165]. It is implicated in several cellular processes such 
as cell proliferation, apoptosis and differentiation [164]. Psoriasin was initially found in 
psoriatic lesions and is produced by keratinocytes in skin and other epithelial surfaces [166]. 
It is present in vaginal fluid and is expressed by epithelial cells in the FRT [144, 167, 168]. 
The antibacterial activity is dependent on its zinc-binding motif and the action is partly 
mediated by zinc sequestration since zinc is an essential element in the metabolism of 
bacteria. Mutation experiments with recombinant psoriasin has confirmed that zinc but not 
calcium binding is of importance for the antibacterial activity [169-171]. Membrane 
disruption is the basis of its antimicrobial activity at low pH [172]. Psoriasin protects the skin 
from colonization and infection by E. coli and is thereby an important effector molecule in 
the cutaneous barrier. In addition, it has been shown that psoriasin expression increases in 
wound exudate after skin barrier disruption [173]. In higher doses, psoriasin also has 
bactericidal effect against Pseudomonas aeruginosa and Staphylococcus aureus [166]. 
Cystein-reduced psoriasin, but not the oxidized form, is an effective broad-spectrum 
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fungicide for numerous dermatophytes and Aspergillus fumigatus. However, direct activity 
towards C. albicans has not been shown [174]. 
The expression of psoriasin is induced in various hyperproliferative and inflammatory skin 
diseases such as atopic dermatitis, mycosis fungoides, Darier disease, lichen sclerosus, actinic 
keratosis and acne inversa and is considered an important effector of the human dermis [164, 
166]. 
Several AMPs such as calprotectin, lysozyme, lactoferrin, secretory leukoprotease inhibitor 
(SLPI), human neutrophil peptides 1-3 (HNP1-3) and HBD 1-2 have been detected in vaginal 
secretions and are produced by the epithelial cells of the FRT [175, 176]. Their importance in 
specific infections is not clarified, however, the cervical mucus plug has been shown to 
exhibit antimicrobial activity against GBS and E coli, but no antifungal activity against C. 
albicans [177]. In one study, women with BV had significantly reduced concentrations of 
AMP in vaginal fluid compared to healthy controls and women with VVC. After adequate 
treatment, the AMP levels in women with BV increased to the levels detected in healthy 
women [178]. The fact that BV is associated with local deficiency of innate immunity may 
result in a state of local immunosuppression that could be the reason for the susceptibility to 
HIV and other sexually transmitted diseases. The higher induction of AMPs in candidiasis is 
considered to be a result of the proinflammatory tissue response during yeast infections [178]. 
 
1.2.3 Adaptive immune defense 
The adaptive immune response is activated when the physical barriers have been penetrated 
and the innate immune response has failed to defeat the invading pathogen. Adaptive 
immunity is characterized by identification of specific antigen determinants of pathogens and 
the ability to distinguish one microorganism from another. B-lymphocytes produce specific 
antibodies, while T-lymphocytes have multiple functions such as to assist in antibody 
production and participate in the cell mediated defense [179]. Ultimately this response is 
efficient and leads to direct elimination of the pathogen in most cases. The adaptive system 
poses an immunological memory which allows a quicker response to a specific antigen when 
the organism faces the same pathogen in the future. 
 
1.2.4 Inflammation and carcinogenesis 
Inflammation is an unspecific defense mechanism activated by tissue damage. It is estimated 
that approximately 15% of worldwide malignancies are related to chronic inflammation. The 
process is complex involving both the innate and adaptive immune systems. The function of 
inflammation is to restore the homeostasis by destroying the source of tissue-threat and repair 
the injury. If the acute disorder is not resolved and instead persists, the inflammation may 
become chronic which demands constant cell renewal. Thereby the inflammation leads to 
extended cell division and an increased risk of mutation and malignant cell transformation 
[180]. Several high-risk HPV genotypes are crucial infections associated with cancer. Other 
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oncogenic viruses are hepatitis-B virus, Epstein-Barr virus and HTLV-1. Prostaglandins are 
released from inflammatory cells by the action of the cyclooxygenase enzymes, COX-1 and 
COX-2, which intensifies the inflammation. The prostaglandin PGE2 which is produced in 
many human tumors and promotes malignant growth is induced by COX-2. It is shown that 
nonsteroidal anti-inflammatory drugs (NSAID) and COX-2 selective inhibitors decrease the 
risk of several cancer forms like colorectal cancer [181, 182]. HPV infection per se is not 
enough for malignant transformation of the infected cell. However, the inflammation 
facilitated by altered immunological mechanisms contribute to the neoplastic process [183-
185].  
1.2.4.1 Antimicrobial peptides in the neoplastic process 
The role of AMPs in carcinogenesis is not yet clarified. Through their involvement in the 
inflammatory process they can modify the microenvironment by promoting or reducing the 
development and cancer progression [186].   
Human beta defensins presumably contribute to both innate and adaptive immune responses 
against HPV induced epithelial lesions. Induction of HBD-2 and HBD-3 has been reported in 
lesions of recurrent respiratory papillomatosis [187], verrucae vulgaris and condyloma 
acuminata, [188]. In benign vulovovaginal condyloma acuminata there was a significant up-
regulation of HBD-1, -2, -3 and psoriasin compared to normal controls [189].  
It has been suggested that HBD-1 acts as a tumor suppressor with high expression in 
precancerous cutaneous lesions and a significant deprivation of HBD-1 expression is seen in 
renal and prostate cancer [190]. In a study using immunohistochemistry, HBD-1 expression 
was analyzed in squamous cell carcinomas and showed lower expression compared to 
premalignant lesions [191]. These findings suggested that the protein expression is decreased 
during the progress to invasive cancer. In an oral squamous cell carcinoma (OSCC) cell line, 
HBD-1 acted as a tumor suppressor by inhibiting cell proliferation [192]. In patients with 
OSCC, HBD-1 was significantly reduced indicating that the lower concentration might 
contribute to the malignant progression [193]. On the other hand, HBD-2 and HBD-3 
increased cell proliferation in vitro and were significantly increased together with psoriasin in 
SCC and SCC-in situ. In anal intraepithelial neoplasia (AIN), HBD-1 expression did not 
differ from unaffected anal mucosa [194] but the expression of HBD-2 and -3 was 
significantly increased.  
When detecting protein concentrations of HBD-1 in cervico-vaginal lavage from patients 
with HSIL, the levels were reduced compared to controls. The same study showed 
significantly lower concentrations of HBD-2 and -3 which is surprising since they are 
typically up-regulated in response to inflammation and infection [195]. Moreover, it has been 
discussed if polymorphism in DEFB1, the gene coding for HBD-1, is associated with the 
ability to clear HPV infection. In a population of Brazilian women two different 
polymorphisms were associated with susceptibility to HPV infection [196]. 
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The cathelicidin LL-37 is overexpressed in ovarian, breast and lung cancer and it has been 
shown that LL 37 can contribute to tumor progression and metastasis [186]. However, LL-37 
has also been shown to have antitumor effect by inducing apoptosis. 
Psoriasin is considered to have the potential to promote tumor progression through various 
signaling pathways [164]. It is involved in keratinocyte differentiation and enhances the 
expression of several differentiation markers. Furthermore, psoriasin stimulates endothelial 
cell proliferation by enhancing vascular endothelial growth factor (VEGF) which is an 
important growth factor in angiogenesis in both chronic inflammation and cancer [197]. In 
several tumors, such as squamous cell carcinoma, breast and bladder cancer, psoriasin is 
overexpressed [191, 198-201]. In estrogen receptor-negative invasive breast carcinoma the 
expression of psoriasin correlates with tumor progression and acquisition of metastatic 
phenotype and is associated with a poor prognosis [202, 203]. Since psoriasin seems to be a 
contributing factor in local tumor progression it might be a valuable diagnostic marker for 
early diagnosis of primary and recurrent squamous cell carcinoma [204, 205]. 
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2 AIMS 
The aims of this thesis were to improve the understanding of the innate immune response in 
in two common infections of the lower female genital tract, recurrent vulvovaginal candida 
infection (RVVC) and HPV induced high grade squamous intraepithelial lesions (HSIL) of 
the cervix.  
  
The specific aims of the studies were: 
 
 To investigate the vaginal NO levels and the expression of iNOS in vaginal biopsies 
before and after treatment of an acute RVVC episode compared to healthy controls 
and to correlate NO levels with symtoms and clincial findings. 
 
 
 To investigate the interaction between C. albicans and epithelial defense mechanisms, 
in particular antimicrobial peptides, during RVVC and possible mode of action of 
psoriasin in the mucosal immunity against C. albicans. 
 
 
 To study the expression of antimicrobial peptides and the proinflammatory cytokine 
IL-8 in HPV induced cervical highgrade squamous intraepithelial lesions before and 
after surgical excision compared to controls. 
 
 
 To study the effect of chlorhexidine digluconate alone and in combination with 
fluconazole on C. albicans eradication and biofilm in RVVC strains. 
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3 PARTICIPANTS 
3.1 SUBJECTS AND ETHICS 
Two groups of patients and three groups of controls were recruited for the studies. In Study I 
and 2 patients with RVVC and healthy women with no history of RVVC were included. The 
inclusion groups in Study III were patients with HSIL and healthy women without HSIL or 
HPV infection. In Study IV, candida strains from patients with RVVC were included together 
with commensal isolates from asymptomatic women. The studies were approved by the 
regional ethics committee in Stockholm. All participants received oral information and signed 
consent was obtained from all participants. 
 
3.1.1 Patients with RVVC 
Fifty-eight women with a history of RVVC were invited for a recruitment visit at the Vulvar 
out-patient Clinic at Danderyd Hospital, Stockholm, Sweden, during an acute episode of 
vulvovaginal candidiasis. Inclusion criteria were age 18-40 years, 3-4 self-reported candida 
infections the last year, symptoms of an acute candida infection and positive culture for C. 
albicans. All patients presented typical symptoms of acute vulvovaginal candida infection at 
the recruitment appointment. Exclusion criteria were severe illness, pregnancy, and other 
genital infections such as Chlamydia trachomatis, bacterial vaginosis and other fungal 
species than C. albicans in cultures. Additional exclusion criteria for all participants were 
vaginal treatments of any kind, vaginal intercourse in the last 24 hours, vaginal douching and 
ongoing menstruation as well as current antibiotic treatment or other medications that may 
influence the immune system. Of these, twenty-eight patients fulfilled the inclusion criteria’s 
and were included in the study (mean age 30 years). None of the participants had used 
antifungal therapy at the time of the first sampling. Patients came for a second study visit 
after completing treatment with oral fluconazole 50 mg per day for one week followed by 
oral fluconazole 150 mg a week for five consecutive weeks. At the second visit, the same 
protocol was used. Recruitment and inclusion flow-chart is shown in Figure 7. Sixteen of the 
same participants were included in Study II (mean age 32 years). C. albicans isolates from 18 
of the RVVC patients (mean age 30) were included in Study IV. 
 
3.1.2 Healthy control women with no history of RVVC 
Forty-seven healthy women with no history of RVVC were invited as potential control 
subjects. They were recruited via advertisement at Karolinska Institutet and hospitals in 
Stockholm. Thirty-one women (mean age 26 years) were included in Study I and twenty-
seven women (mean age 26) were included in Study II. The exclusion criteria were the same 
as for patients. The controls had a one single appointment and had not used anti-fungal 
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treatment before the examination. In Study IV, 19 commensal strains from asymptomatic 
women were used as controls. 
 
 
Figure 7. Flow-chart showing the recruitment procedure of patients with RVVC and healthy controls 
to Study I. 
 
3.1.3  Patients with HSIL 
Women referred to the gynecology outpatient clinic at Danderyd Hospital, Stockholm from 
the National cervical screening program with smears results indicating HSIL were invited to 
participate. The inclusion criteria were age 18-40 years and diagnosis of CIN 3 verified in 
surgical specimens after cervical conisation by two independent pathologists. Exclusion 
criteria were the same as in Study I, II and IV. 
After vaginal cultures and histo-pathological analyses were completed, nineteen women 
(mean age 30 years) with HSIL were included in Study III, Figure 8. 
All patients were treated with cervical conisation (laser or loop excision) and came back for a 
second visit 6 months after surgery. All examinations and samplings were repeated at the 
follow up, according to the same protocol as during the first visit. 
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3.1.4 Healthy controls with no HSIL 
Fourteen women (mean age 31 years) with no history of LSIL or HSIL were enrolled as 
healthy controls. The exclusion criteria were identical as for the controls in Study I, II and IV.  
 
 
Figure 8. Flow-chart showing the recruitment procedure of patients with HSIL and healthy controls to 
Study III. 
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4 METHODS 
4.1 QUESTIONNARIES 
All participants filled in a study specific questionnaire surveying age, occupation, smoking 
habits, ongoing medication and contraception use. In addition, a medical history including, 
gynecological and reproductive history was taken. For current symptoms of RVVC, a 
thorough description of discharge, pruritus dryness, soreness and pain was obtained. A 
symptom score was created, ranging from 0 to 5, based on the number of reported symptoms.   
 
4.2 NO-MEASUREMENT 
Measurement of NO levels were achieved prior to the gynecological examination since 
manipulation of tissue may increase the levels of NO metabolites, likely because of the 
mechanical provocation [206]. The method of NO measurement in the vagina was described 
by Sioutas et al [207] and has also been evaluated for use in the uterine cavity by the same 
group [208]. NO levels were measured by using a small all-silicon catheter. The catheter 
balloon was positioned in the vagina and filled with 25 ml room air, Figure 9. After five 
minutes’ incubation, the air was aspirated into a syringe and directly injected into a 
chemiluminescence analyzer (CLD 77 AM, Eco Physics) for measurement of NO levels as 
parts per billion (ppb). The level of NO in the ambient air was measured and subtracted from 
the NO levels measured in the vagina.  
 
 
Figure 9. NO measurement in vagina with a catheter balloon. 
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4.3 EXAMINATION AND SAMPLING 
A thorough gynecological examination was made with inspection of the tissues in the vulva 
and vagina. Microscopy of wet mount with saline and 10% potassium hydroxide (KOH) was 
performed and specimens for microbiological culture and chlamydia PCR were collected. 
Amsel’s criteria were used for exclusion of bacterial vaginosis (vaginal pH>4.5, positive 
whiff test, homogenous vaginal discharge and presence of clue cells) [209].  
Based on the clinical findings of vaginal erythema, pathological discharge, dry vulvar skin, 
fissures and visible hyphae in wet mount an examination score was created. Each positive 
finding generated one point (0-5), Table 3. 
In Study II, vaginal lavage was obtained by intravaginal administration of 5 milliliters of 
distilled water. After 5 minutes the lavage fluid was collected through a small catheter. The 
fluid was centrifuged at 300xg for 10 minutes and then sterile-filtrated. The cell pellet and the 
supernatant were stored separately at -80°C. 
Sampling of mucus from the cervical canal for Study III, was performed using a cytobrush 
[210]. The cytobrush was stirred for 1 min in a test tube containing 3 ml of sterile water 
before centrifugation at 300xg for 10 min. The cell pellet and the supernatant were stored 
separately at -80°C. 
The vaginal biopsies for Study I and II was obtained with 3 mm forceps at the 3 and 9 o´clock 
positions approximately 3-4 cm from the vaginal introitus. Before obtaining the biopsy, 2 mL 
of the local anesthetic lidocaine was injected in the tissue. One biopsy was fixed in 4% 
paraformaldehyde at 4°C overnight, transferred to 70% ethanol and processed for 
immunohistochemical analysis. The second biopsy was placed in RNA-later RNA 
Stabilization Reagent (Qiagen) and subjected to RNA isolation and gene expression analysis. 
For Study III cervical forceps biopsies of 3 mm were obtained from the cervical 
transformation zone after colposcopy. One biopsy was sent for histo-pathological analysis. A 
second biopsy was prepared for RNA analysis and a third biopsy was processed for IHC. 
 
4.4 IDENTIFICATION AND ISOLATION OF C. ALBICANS 
For identification of C. albicans, vaginal swabs were cultured on CHROMagar. Candida and 
typical colonies were further identified by latex surface antigen agglutination (Bichro-Dubli). 
Absence of fungal and bacterial growth in the control participants was confirmed according 
to the same procedure. Isolates were kept frozen at -80°C. For experiments, if not stated 
otherwise, isolates were cultured on Sabouraud agar for 1-2 days at 37°C and then in yeast 
peptone dextrose (YPD) medium overnight at 30°C. This culture was diluted 1:100 in fresh 
medium and grown for another 3 hours at 30°C to the logarithmic growth phase. Under these 
conditions, C. albicans grew as yeast cell. 
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4.5 IMMUNOHISTOCHEMISTRY 
Biopsies collected for immunohistochemical analysis were paraffin-embedded and cut at 4μm 
and mounted onto glass slides. 
For Study I immuno-staining for iNOS was manually performed using EnVision™ 
Peroxidase/DAB Detection System kit, according to instructions provided by the 
manufacturer. The specificity of the immune-staining was confirmed by lack of staining after 
omitting the primary antibody. Staining for NADPH-d or iNOS was performed 
simultaneously on all sections to avoid variability in staining intensity. A semi-quantification 
of the general iNOS staining was defined as absent=0, mild=1, moderate=2 or intensive=3 by 
two independent investigators blinded to the protocol using a Zeiss Axiophot microscope. 
For Study II and III the sections were de-paraffinized in xylene or Neo-Clear, rehydrated in 
an ethanol gradient and washed in water and phosphate-buffered saline (PBS) and thereafter 
prepared according to an IHC protocol. Overnight incubation with primary antibodies was 
carried out at 4°C. Primary antibodies used were rabbit anti-HBD1 (1:100, Santa Cruz 
Biotechnology) (Study II), goat anti-HBD2 (1:50, R&D Systems,),(Study II), rabbit anti-
HBD3 (1:100, Santa Cruz Biotechnology)(Study II), rabbit anti-psoriasin (1:800, 
Abcam,)(Study II and III), and rabbit anti-RNase 7 (1:500, Novus Biologicals)(Study II). 
Sections were then incubated with Alexa Fluor-conjugated secondary antibodies mounted in 
medium with DAPI (Life Technologies). Images were acquired on a Leica SP5 (Wetzlar,) 
confocal microscope using a 40× objective. 
 
4.6 TOTAL RNA EXTRACTION AND REAL-TIME PCR ANALYSIS 
Total RNA extraction from biopsies and cultured cells was extracted using the RNase Mini 
kit (Qiagen). In Study II reverse transcription with up to 1 μg of RNA was carried out using 
the DyNAmo cDNA Synthesis Kit (Finnzymes,) or the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). In study III the concentration and purity of RNA 
were determined with Nanodrop, and up to 1 μg of RNA was transcribed to cDNA using the 
High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific).  
Gene expression was analyzed with TaqMan gene expression assays (Thermo Fisher 
Scientific Baltics,) for AMPs and cytokines as shown in Table 1. Expression of RNase 7 was 
examined using a SYBR Green-based assay (Qiagen). 
Human GAPD (GAPDH, 4326317E) and 18S rRNA was used as housekeeping controls to 
calculate relative expressions of target genes. 
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Table 1. Analyzed genes by PCR 
 
 
4.7 WESTERN BLOT  
For detection of psoriasin in cell pellets, cells were lysed and cleared by centrifugation and 
the protein concentration was determined by BCA assay. Equal amounts of protein were 
heated and subjected to polyacrylamide-gel-electrophoresis and the separated samples were 
transferred to PVDF membranes. After transfer, membranes were blocked and incubated with 
a polyclonal rabbit anti-psoriasin (1:800 in milk-TBST) antibody. Incubation with an anti-
rabbit HRP-conjugated secondary antibody was carried out and signals were detected. 
 
4.8 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA) 
In Study II vaginal lavage samples were analyzed using ELISA kits for HBD -1, -2 and 3, 
psoriasin, LL-37, human ribonuclease (RNase) 7 and IL-8 according to the manufacturer’s 
instructions.  
In Study III the supernatant from the cervical secretion samples were analyzed using ELISA 
kits for psoriasin and IL-8 and were carried out according to the manufacturer’s 
recommendations. The levels of psoriasin and IL8 in each sample were presented as the ratio 
of the proteins and the total protein content in secretion samples determined by using BCA 
assay.  
 
4.9 CHEMICALS AND REAGENTS 
Psoriasin was purified from human skin [211], dissolved in 0.01% acetic acid to a 
concentration of 1 mg/ml and stored at -20°C. A vaginal fluid simulant (VFS) was used as 
medium for all reactions to mimic the vaginal milieu. This previously described formulation 
resembles the vaginal material with respect to pH, osmolarity and chemical composition 
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[212]. Organic acids are represented by lactic and acetic acid and proteins by albumin. All 
mono- and polysaccharides were purchased from Sigma; working dilutions were prepared 
freshly in VFS. 
 
4.10 CANDIDA ADHESION ASSAY 
To determine the adhesive capacity of C. albicans isolates, a microtiter plate assay, using 
VFS as medium or vaginal lavage was used [142]. C. albicans yeast cells from the 
logarithmic growth phase were accumulated by centrifugation and washed twice in PBS. The 
pellet was dissolved in VFS and the density was adjusted spectrophotometrically. A 100-µl 
volume containing approximately 1×106 CFU was inserted to wells on 96-well sterile, non-
treated, flat-bottomed microtiter plates and incubated for 30 min at 37°C with low agitation 
(100 rpm). Thereafter, wells were washed with PBS to eliminate non-adherent cells, and the 
amount of adherent cells were quantified by metabolic activity using a XTT assay. Psoriasin 
(0.001-1 µM or vector) was added to duplicate wells to investigate the influence of psoriasin 
on C. albicans adhesion. In selected experiments, psoriasin (1 µM or vector) was pre-
incubated with polysaccharides β-(1,3)-D-glucan, D-mannan and chitin (1 mg/ml in VFS) for 
30 min before the addition of C. albicans. To evaluate the effect of vaginal lavage on 
adhesion, VFS was replaced by vaginal lavage fluid from patients and control participants.  
 
4.11 PSORIASIN – CANDIDA BINDING ASSAYS 
To demonstrate binding between C. albicans cells and psoriasin, a pull-down assay was 
modified from a previously described protocol [142]. Approximately 1.5×107 cells were 
incubated with 10 µg psoriasin in VFS (final volume 250 µl) and incubated for 30 min with 
agitation; alternatively, 250 µl of vaginal lavage was used. Cells were collected by 
centrifugation and washed with VFS. Binding of psoriasin to polysaccharides was 
investigated in a similar manner. Because of the solubility of mannan, mannan-agarose was 
used in the test. β-(1,3)-D-glucan from baker’s yeast, chitin from crab shells (0.25 mg/ml) or 
mannan-agarose (30 µl) were mixed with 10 µg psoriasin in VFS (final volume 750 µl) and 
incubated overnight with agitation. Polysaccharides were then pelleted by centrifugation and 
washed with VFS. The final pellets were heated in tricine sample buffer and Western blot 
was performed. 
 
4.12 CELL CULTURE AND CELL INFECTION 
The vaginal epithelial cell line AO was used as model of the vaginal epithelium. Cells were 
cultured in EpiLife Medium with 60 µM calcium and supplemented with Human 
Keratinocyte Growth Supplement in a humidified incubator at 37°C with 5% CO2. C. 
albicans from logarithmic growth were collected by centrifugation, washed in PBS and 
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aliquots of 3×107 cells were transferred in low-binding 1.5-ml tubes. Cells were collected by 
centrifugation and the pellet was suspended in 98 µl VFS with 2 µl psoriasin (1 mg/ml) or 
vector. The supernatant was discarded and the pellet suspended in 200 µl 0.2% 
paraformaldehyd (PFA) in PBS. Cells were suspended in cell culture medium to a final 
concentration of 107 CFU/ml. From this suspension, 100 µl was added to a well of confluent 
AO cells containing 900 µl of fresh cell culture medium and incubated for 6 hours in a 
humidified incubator. The medium was removed and cells were collected for RNA extraction 
and gene expression analysis. All conditions were analyzed in duplicate. 
 
4.13 TRANSMISSION ELECTRON MICROSCOPY 
Transmission electron microscopy of C. albicans incubated with psoriasin or vector (control) 
for 30 min at 4C was performed. β-glucan was marked with immunogold-labelled anti- β-
glucan antibodies. The cell wall thickness from non-treated and psoriasin-exposed cells in 5-8 
images per experiment was measured, three independent experiments were performed.   
 
4.14 MICROTITER METHOD TO MEASURE C. ALBICANS BIOFILM 
To measure the ability of C. albicans to adhere and form biofilm, the crystal violet assay in 
polystyrene microtiter plates was performed. C. albicans were grown for 48h in YPD at 30°C 
without shaking. Biofilm was stained with crystal violet (0.3%). The dye was solubilized with 
80% ethanol and 20% acetone and the optical density was measured at 570 nm. 
 
4.15 CRYSTAL VIOLET METHOD TO ANALYZE THE EFFECT OF 
CHLORHEXIDINE DIGLUCONATE AND FLUCONAZOLE ON BIOFILM AND 
C. ALBICANS 
The effect of chlorhexidine digluconate (0.02%, GlaxoSmithKline) and fluconazole (4ug/ml, 
F8929, Sigma) was evaluated on biofilm and growth of C. albicans. The effect of 
chlorhexidine digluconate on formation of biofilm were analyzed using the crystal violet 
method. Each candida strain, in concentration 5 x 106, was treated with 0.02% of 
chlorhexidine digluconate for 48 h, in 30C. Planktonic cells were removed, wells were 
washed twice with PBS and then stained for 10 minutes with 0.3% crystal violet. After 
removing crystal violet and washing, a solution of acetone and ethanol was used to dissolve 
the remaining crystal violet stains from the biofilm, the OD was analyzed using 
spectrophotometer at 570 nm.   
To investigate the effect on mature biofilm on the other hand, formation was allowed for 48 
hours, before chlorhexidine digluconate 0.02% or fluconazole 4 µg/ml or a combination of 
chlorhexidine digluconate and fluconazole were added for 24 h. The optical density of the 
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chlorhexidine digluconate treated group with or without fluconazole was compared with an 
untreated control group. 
 
4.16 ENUMERATION OF C. ALBICANS IN MATURE BIOFILM 
C. albicans were enumerated, following biofilm formation and exposure to chlorhexidine 
digluconate, fluconazole and the combination of chlorhexidine digluconate and fluconazole 
or medium alone. To investigate if the tested drugs had impact on the mode of candida 
growth, the number of planktonic cells as well as cells within the biofilm were analyzed. 
Planktonic candida cells detected in the medium were estimated by viable count after serial 
dilutions in PBS. To assess the number of candida in the already established, mature, biofilm, 
the biofilm was first washed twice with PBS and then scraped from the microtiter plate. The 
biofilm was dissolved in 200 µl PBS, and serially diluted before viable count was performed. 
Dilutions were plated on blood agar plates followed by overnight incubation in 37C and 
results from cells exposed to test drugs or medium alone were calculated. 
 
4.17 STATISTICS 
The IBM SPSS Statistics for Windows (Version 22, 0,) and GraphPad Prism, version 5 and 6 
(GraphPad Software) were used to analyze the data. For comparison of clinical characteristics 
between patients and controls, either Student T-test or Fischer´s exact test were used as 
appropriate. Data obtained from clinical materials were analyzed with non-parametric tests, 
results presented as individual values with median. For matched comparisons, the Wilcoxon 
signed rank test or Friedman test was used, whereas comparison between groups was 
performed by Mann Whitney or Kruskal-Wallis tests. For correlating numeric and categorical 
variables such as vaginal NO levels to the symptom and examination scores, the Spearman’s 
rank correlation test was used and Pearson correlation coefficient for comparisons of numeric 
variables, such as mRNA and protein levels of psoriasin and IL-8. Multiple comparisons of 
AMPs in Study II were analyzed by unpaired t-test, one-way ANOVA and Dunnett’s 
multiple comparison tests, or two-way ANOVA and Bonferroni’s multiple comparison, 
which was also used for analyzing the formation of treated and untreated biofilm and cell 
growth by viable count in Study IV. Data from other in vitro experiments in Study II are 
presented with mean and standard deviation from at least three independent experiments 
performed in at least duplicate. Variations in the number of participants included were due to 
limited material and biological outliers were not excluded, whereas technical outliers were 
detected by Grubb’s test and excluded. All tests were performed two-sided and differences 
with P-values of <0.05 were considered statistically significant.  
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5 RESULTS 
5.1 STUDY I: NITRIC OXIDE IN RECURRENT VULVOVAGINAL CANDIDIASIS 
5.1.1 Clinical background 
The clinical background of patients and healthy controls in Study I are shown in Table 2. 
Table 2. Clinical data of participants 
 
 
The patients were older and reported significantly higher numbers of previous condyloma and 
BV. However, they did not have a history of more frequent other genital infections or cervical 
dysplasia compared to the healthy controls. No other differences were detected between the 
groups. 
 
5.1.2 Symptoms and clinical findings 
When patients came for the recruitment visit they reported symptoms associated with 
vulvovaginal candida infection. Most patients presented with several symptoms and clinical 
findings of VVC. According to the inclusion criteria, all patients had C. albicans in culture. 
At the follow up visit after treatment, the symptom and examination scores were significantly 
lower (p<0.001), Table 3. However, four patients had positive culture and six patients had 
visible hyphae in wet-mount. One of the patients had symptoms of pruritus and both positive 
culture and visible hyphae. Five controls with no clinical signs of candida infection had 
hyphae in wet-mount. 
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Table 3. Symptoms and clinical findings 
 
Comparisons:  a + c) patients before and after treatment p < 0.001, b + d) patients before treatment and 
controls p <0.001.  
 
5.1.3 NO levels in patients and controls 
Patients with acute infection of VVC displayed median vaginal NO levels of 352 ppb (range 
0-6178) compared to a median of 6 ppb (range 0-43) in healthy controls, p<0.001, Figure 
10a. When fluconazole treatment for six weeks were completed, the NO levels in the patients 
were reduced to a median of 18 ppb (range 0-163), p <0.001, Figure 10b. The levels were 
however significantly higher compared to the controls, p= 0.003. After treatment, four of the 
patients displayed positive candida cultures, but did not have symptoms of infection. A post 
priori analysis was performed, including only patients with negative cultures, showing that 
the NO levels were yet higher in patients after treatment, median (22 ppb, range 0-131), 
compared to healthy controls (median 6 ppb, range 0-43), p<0.005. The method of NO 
measurement in vagina was well accepted and there were no reports of distress during the 
testing procedure. In one patient and two controls the measured NO levels were lower than 
the concentration in ambient air. In those cases, the values were considered outliers and were 
set to 0 for statistical purposes.  
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a)                                                                            b) 
 
Figure 10. a) Median levels of vaginal nitric oxide in heathy controls and in women with RVVC 
during an acute exacerbation (ppb=parts per billion). The scale is logarithmic, the dotted lines 
represent 25 and 50 ppb, b) Vaginal NO levels in women with RVVC before and after six weeks of 
treatment with fluconazole (ppb=parts per billion). 
 
To evaluate vaginal NO measurements as a diagnostic tool and the examination score for 
predicting true clinical cases ROC analyses were performed, Figure 11. Calculations of 
sensitivity and specificity for various cut-off levels for NO were used to estimate the 
effectiveness of NO as a diagnostic tool for vulvovaginal candidiasis. The sensitivity was 
0.75 for the cut-off level of NO 50 ppb and specificity 1.0. For NO 25 ppb, the sensitivity 
was 0.86 and specificity 0.81, Figure 10a. 
 
      a)                                                             b) 
 
Figure 11. Roc analyses. Twenty-eight patients with acute vulvovaginal candida infection and 31 
healthy controls. a) NO measurement, area under the curve 0.911, p<0.001 b) Examination score, 
area under the curve 0.995, p<0.001. 
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5.1.4 iNOS expression 
The expression of iNOS was investigated in patients before and after antifungal therapy 
compared to healthy controls. A difference of the expression within the epithelium was 
detected. Distinct iNOS staining in the basal cell layers of the epithelium was significantly 
more common in patients during acute infection (70%) than in controls (20%), p=0.034, 
Figure 12 a-b. After treatment, the staining in the basal cell layers was still present more 
often in patients (67%) than in controls (20%), p=0.022. When analyzing the overall iNOS 
staining in the epithelium, no differences were seen between patients before and after 
treatment compared to controls. No correlations were found between NO levels and iNOS 
staining. 
 
   a)                                               b)             
 
Figure 12. a) Patient with iNOS immunostaining of the epithelial lining and a distinct iNOS 
expression at the basal membrane layer, b) Healthy control with iNOS immunostaining of the 
epithelial lining, without a distinct iNOS expression at the basal membrane layer. 
 
The results before treatment show a positive correlation between vaginal NO levels and 
examination score, rs = 0.677, p<0.001, and symptom score, rs =0.644, p<0.001. After 
treatment when the NO levels were reduced, no correlations to the examination score, rs = 
0.083 (ns) or symptom score, rs =0.236 (ns) persisted. 
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5.2 STUDY II: PSORIASIN, A NOVEL ANTI-CANDIDA ALBICANS ADHESIN 
5.2.1 Clinical background 
Six-teen patients with RVVC and 27 healthy controls were included in the study. The 
controls were younger than the patients, p=0.04. All patients had verified C. albicans at the 
first visit, but were culture negative at follow up. There was no difference in contraceptive 
use between patients and healthy controls. 
 
5.2.2 Expression of antimicrobials proteins and peptides in the vaginal 
epithelium. 
The expression of six epithelial AMPs were analyzed in vaginal biopsies and vaginal lavage 
from healthy women (n=27). Psoriasin, encoded by the S1007A gene and RNase 7 presented 
the highest mRNA and protein levels, Figure 13.  
 
  
Figure 13. m-RNA expression and protein levels of antimicrobial proteins in vaginal tissue and 
vaginal lavage in healthy women. 
 
The mRNA and protein levels of the AMPs were analyzed during acute C. albicans infection 
and after completed antifungal treatment. RNase 7 was not increased in response to candida 
and was not further analyzed. However, psoriasin was strongly up-regulated during the acute 
infection episode of RVVC, both on mRNA level, Figure 14a, and on protein level as shown 
by immunohistochemistry, Figure 15. However, the levels of psoriasin in the supernatant of 
vaginal lavage was not significantly elevated during infection, Figure 14b.  
 
 
  35 
 
   a) b) 
 
Figure 14. a) Expression of psoriasin, S100A7, mRNA in controls and patients during infection and 
after treatment. b) Psoriasin levels in vaginal lavage samples. ***P<0.001, ****P<0.0001. 
 
 
Figure 15. Immunohistochemistry in tissue sections, psoriasin: green; cell nuclei: blue. 
 
Increased levels of psoriasin during infection were identified shown by Western blot in the 
pellet of the vaginal lavage containing desquamated mucosal cells and yeast. Figure 16. 
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Figure 16. Psoriasin-specific bands on 
Western blots were quantified, intensity is 
expressed in arbitrary units (AU) 
**p<0.01, ***p<0.001 
 
 
5.2.3 Psoriasin interacts with β-glucan in the Candida cell wall 
A possible interaction between psoriasin and the candida cell wall was investigated since 
psoriasin formed during acute candida infection was associated with the cell pellet, Figure 
16. A pull-down assay was performed using candida cells and the polysaccharides β-glucan, 
chitin and mannan, which are important elements of the fungal cell wall. Both purified 
psoriasin and psoriasin present in vaginal lavage bound intensely to candida cells and to β-
glucan, whereas binding activity by psoriasin to chitin and mannan was weak, Figure 17. 
 
 
Figure 17. C. albicans cells and cell wall polysaccharides were incubated with purified psoriasin or 
vaginal lavage. 
 
A significant thinning of the cell wall in psoriasin-exposed C. albicans was revealed by 
electron microscopic investigation, p<0.05, Figure 18a–b. Furthermore, reduced content of β-
glucan in the psoriasin affected candida cells was shown by immunogold-labelling of the 
protein, Figure 18a.  
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a)                                                                                   b) 
 
                                                                                                            
Figure 18. a) C. albicans incubated with psoriasin or vector (Control), investigated by transmission 
electron microscopy, scale bars 1 µm (upper panel); β-glucan was marked with immunogold-labelled 
anti- β-glucan antibodies (lower panel, enlarged). b)  Thickness of cell wall from non-treated (Co) 
and psoriasin-exposed cells (Psoriasin), measured as exemplified in the close-up. 
 
5.2.4 Psoriasin inhibits C. albicans adhesion to surfaces 
The effect of psoriasin-mediated changes of the candida cell wall was analyzed by exploring 
adhesion of candida in settings simulating the vaginal environment [212]. Psoriasin 
diminished the adherence of C. albicans cells to polystyrene in a concentration-dependent 
manner, Figure 19a. β-glucan had the capacity to neutralize the anti-adhesive properties of 
psoriasin, which was not seen with chitin or mannan, Figure 19b.  
A similar assay with samples from healthy controls and from patients with acute candida 
vulvovaginitis was performed to confirm the effect in vaginal lavage. An anti-adhesive 
activity was shown in vaginal lavage from patients with candida infection and it could, to 
some extent, be blocked by β-glucan, Figure 19c. 
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                 a)                                                                     b) 
c) 
 
Figure 19. Psoriasin reduces candida adhesion. a) Adhesion of C. albicans in vaginal lavage simulant 
with different concentrations of psoriasin, b) Adhesion of C. albicans with psoriasin pre-incubated 
with polysaccharides. Data are expressed in relation to corresponding samples without psoriasin 
(Control, Co, =100), c) Candida adhesion analyzed in vaginal lavage samples from healthy controls 
and patients with recurrent vulvovaginal candidiasis, and in the presence of glucan (n = 18).  
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5.2.5 Epithelial immune response to C.albicans is enhanced by psoriasin 
Vaginal epithelial cells were infected with psoriasin-treated and non-treated fungal cells to 
investigate the consequence of psoriasin binding to C. albicans. The induction of pro-
inflammatory cytokines was influenced by psoriasin treatment of candida cells, the most 
pronounced effect seen in IL-8 response, Figure 20a. Accordingly, IL8 mRNA levels in 
patients during acute infection showed a positive correlation with levels of psoriasin mRNA, 
Figure 20b. However, psoriasin alone did not influence IL-8 expression in epithelial cells in 
vitro. 
 
a)                                                                                      b) 
 
 
Figure 20 a) mRNA levels of proinflammatory cytokines in vaginal epithelial cells after infection with 
C. albicans, untreated or pre-treated with psoriasin. b) Correlation between psoriasin mRNA 
(S100A7) and IL8 expression in vaginal tissue from women during an acute infection with C. albicans, 
r=0.55, p<0.05.  
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5.3 STUDY III: PSORIASIN EXPRESSION IN CERVICAL HSIL 
5.3.1 Clinical background 
The clinical background of patients and controls are shown in Table 4. There were no 
differences regarding age, BMI, parity, smoking habits or contraceptive use and the history of 
genital infections was comparable. Three patients described previous low grade cervical 
dysplasia (LSIL).  
 
Table 4. Clinical data of participants 
 
 
The final inclusion of patients (n=19) was determined by the HSIL diagnosis in the surgical 
specimen after conisation. At the follow up visit, six months after surgery, three patients had 
mild atypia in liquid-based cytology. No dysplasia was found in the biopsies of 14 patients 
and mild dysplasia (LSIL) was diagnosed in one patient who had normal cytology. 
Unfortunately, four patients declined the biopsy procedure. Before surgical treatment all 
patients were positive for HR HPV. At the follow up after conisation, all but two were HPV 
negative. The HPV positive patients were among the women with mild atypia and 
subsequently needed further clinical attendance. All controls were HPV negative and had 
benign cytology and biopsies at the recruitment visit. 
 
5.3.2 The expression of psoriasin 
At the first visit before surgical treatment, psoriasin mRNA expression was lower in patients 
compared to controls, p=0.05, Figure 21a. Six months’ post conisation, the mRNA 
expression was significantly increased and reached similar levels as in the healthy controls, 
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p=0.04, Figure 21a. The protein levels of psoriasin increased significantly after conisation, to 
levels comparable to those seen in controls, p=0.03, Figure 21b.  
a)                                                                 b) 
21. Psoriasin in cervical samples from patients with HSIL before and after conisation compared to 
healthy controls. a) mRNA expression analyzed by real-time PCR    b) Protein levels in secretion 
samples from the cervical canal analyzed by ELISA. 
 
Immunohistochemistry showed that psoriasin is mainly localized in the cytoplasm of the 
upper epithelial cells. After conisation, the immunostaining was pronounced as opposed to 
the weak staining of the HPV infected pre-surgical biopsies, Figure 22 a-c. 
 
a)                                               b)                                              c)  
 
Figure 22. Immunohistochemistry of representative sections (40x objective) from patient with HSIL 
and healthy control. Epithelial cells with psoriasin staining of the cytoplasm (green) and DAPI to 
show nuclei (blue). a) Healthy control b) Patient before treatment c) Patient after treatment. Scale bar 
20.0 µm. 
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5.3.3 The expression of IL-8 
The proinflammatory cytokine IL-8 was chosen as an indicator of the inflammatory response 
in cervical tissue. The relative expression of IL-8 mRNA was significantly higher in patients 
before treatment than six months after conisation, p=0.05. No differences were observed 
compared to controls, Figure 23a. On the protein level, no differences were observed in 
patients before or after treatment nor compared to controls, Figure 23b. 
 
      a)                                                                    b) 
 
Figure 23. IL-8 in cervical samples from patients with HSIL before and after conisation compared to 
healthy controls. a) mRNA expression in biopsies analyzed by real-time PCR.  b) Protein levels in 
secretion samples from the cervical canal analyzed by ELISA. 
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5.4 STUDY IV: NEW TREATMENT STRATEGY OF RVVC  
5.4.1 Participants and samples  
C. albicans was isolated in vaginal swabs from 18 women, during an acute episode of 
candida infection and with a history of 3-4 candida infections in the last year. For controls, C. 
albicans isolates from 19 asymptomatic women were collected, referred to as commensals 
and included for control purposes.  
5.4.2 Fluconazole has limited effect on RVVC strains in mature biofilm 
Biofilm has an ability to prevent the antimicrobial action of both the innate immunity and 
antimicrobial treatments. Therefore, the effect of FLZ on C. albicans growth in already 
established biofilm as well as the effect of planktonic cell was investigated, Figure 24a-c. 
There was a significant decrease of planktonic candida cells growing exterior to the biofilm 
after FLZ treatment (p<0.0001), Figure 24b.  However, no effect was observed on candida 
growing within the biofilm, Figure 24c. Likewise, FLZ did not affect the biofilm per se, 
Figure 24a. 
 
a) Mature biofilm                       b)   Planktonic cells                      c)   Cells within biofilm 
 
Figure 24. Thickness of established, mature biofilm (a), produced by vaginal C. albicans isolates 
(n=18), was measured. The effect of chlorhexidine digluconate (CHG) and fluconazole (FLZ) and the 
combination CHG + FLZ was investigated. As controls served untreated C. albicans from the same 
patients. Individual and median values are presented, depicted as optical density (OD) at 570 nm after 
dissolution of crystal violet. Viable count of planktonic C. albicans (b) and of C. albicans within 
mature biofilm (c). * p<0.05, ** p<0.01, **** p <0.0001 
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5.4.3 Chlorhexidine digluconate dissolves established biofilm of RVVC 
strains and inhibits candida growth 
Since FLZ had a rather poor effect on candida growth and biofilm, an alternative treatment 
approach was investigated. The effect of CHG treatment alone and in combination with FLZ 
on C. albicans growth and biofilm was analyzed, Figure 24a-c. Mature biofilms of RVVC 
strains were significantly reduced after CHG exposure which was not shown after FLZ 
treatment, Figure 24a. Furthermore, candida cell growth both in planktonic state and within 
biofilm was significantly reduced by CHG treatment. An additional effect of combined CHG 
and FLZ was seen, but did not reach statistical significance, Figure 24b-c. Moreover, there 
was no statistical difference observed comparing the effect of CHG alone and in combination 
with FLZ on established biofilm. However, a sub-analysis of paired samples revealed that all 
pathogenic strains except two, had lower amount of CFU/ml when FLZ was added as a 
combined treatment, data not shown.  
 
5.4.4 Biofilm formation can be inhibited by chlorhexidine digluconate in 
RVVC strains 
Based on the effect of CHG on mature biofilm, we sought to investigate if CHG also could 
inhibit formation of new biofilm and C. albicans growth. We observed that 0.02% CHG was 
able to prevent the formation of biofilm as well as candida growth in planktonic and biofilm 
state, in RVVC strains, Figure 25 a-c. 
 
a) New biofilm                          b)   Planktonic cells                    c)    Cells within biofilm 
 
Figure 25. The effect of chlorhexidine digluconate was investigated on formation of new C. albicans 
biofilm (a). C. albicans were obtained from patients with RVVC (n=18) and from asymptomatic 
women, commensal strains (n=19). Untreated strains served as controls. Individual and median 
values are presented, depicted as optical density (OD) at 570 nm after dissolution of crystal violet. 
Viable count of planktonic C. albicans (b) and of C. albicans in newly formed biofilm (c). 
****p<0.0001 
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5.4.5 Commensal C. albicans growth and biofilm is affected by 
chlorhexidine digluconate 
Commensal C. albicans isolates were studied and the capacity to form biofilm did not differ 
from RVVC strains, Figure 26a and 24a. However, contrary to in RVVC strains, CHG as a 
single treatment and in combination with FLZ did not reduce mature biofilm in commensal 
strains, Figure 26a. Furthermore, in line with the results from RVVC strains, CHG alone and 
in combination with FLZ was able to inhibit candida growth both in the planktonic phase and 
within established biofilm, Figure 26b-c. 
 
a) Mature biofilm                      b)   Planktonic cells                     c)   Cells within biofilm 
 
Figure 26. Thickness of mature biofilm (a) produced by colonizing vaginal C. albicans isolates (n=19) 
was measured after treatment of chlorhexidine digluconate (CHG) and fluconazole (FLZ) and the 
combination CHG + FLZ. As controls served untreated C. albicans from the same patients. Individual 
and median values are presented, depicted as optical density (OD) at 570 nm after dissolution of 
crystal violet. Viable count of planktonic C. albicans (b) and of C. albicans in mature biofilm (c) from 
asymptomatic women, commensal isolates. *** p<0.001, ****p<0.0001 
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6 DISCUSSION 
6.1 DISCUSSION OF THE RESULTS 
6.1.1 NO levels, symptoms and clinical findings 
The pathogenesis of RVVC still remains an enigma. There has been progress in the 
understanding of the disease but the picture is complex with many factors to consider, such as 
individual differences in susceptibility to recurrent infections, diverse local immune 
responses and virulence factors of various candida strains. A strong inflammatory response is 
seen in the vaginal mucosa during relapse of RVVC. During the acute infectious episode, 
vaginal NO levels are significantly increased compared to after treatment as well as compared 
to those in healthy controls. In the current study we showed that vaginal NO concentration 
also correlates to clinical findings and symptoms in RVVC. It is not yet clarified if the 
inflammatory tissue response is the same in RVVC and sporadic VVC even though clinical 
findings are similar.  
NO is part of the non-specific host defense and is involved in the inflammatory process. The 
immuno-histochemical results demonstrating iNOS expression in the mucosa indicate that the 
NO measured in the vagina most likely derives from epithelial iNOS. These results are 
supported by the inflammatory status of the vulvovaginal skin and mucosa with erythema, 
edema and discharge. An interesting finding was the distinct staining of iNOS in the 
epithelial basal membrane that has not been described before. No correlations were found 
between NO levels and overall iNOS staining, but the basal membrane staining may still 
mirror an amplified expression of iNOS in patients. Previous studies of chronic inflammatory 
disorders have described mucosal iNOS located in the upper part of the epithelium facing the 
lumen of several hollow structures [213], a finding that was replicated in our material. 
Increased vaginal NO concentration has been reported in a study including patients with 
unspecific vaginitis [207]. Therefore, to eliminate other possible influences of NO formation 
that could interfere with our results, we stringently excluded participants with other cervical 
or vaginal infections.  
After antifungal therapy the vaginal NO levels in patients were decreased but still 
significantly higher compared to levels in healthy controls. A possible explanation of this 
finding might be that mucosal inflammation was still not entirely resolved. 
It is still not known if formation of NO in the vagina is beneficial or harmful for the tissue. 
Normally, high concentrations of NO are found in the nasal airways without harming the 
tissue [213]. However, NO is known to have double functions and may induce damage to 
host cells. Destructive effects of NO likely arise from products, following the reaction of NO 
with oxygen radicals. In patients with active inflammatory bowel disease, the median NO 
concentration in rectum was ten times higher than the levels we reported in RVVC [125]. 
However, in unspecific vaginitis, non-infectious cystitis and asthma as well as in bacterial 
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infections such as cystitis and pelvic inflammatory disease, the NO levels were in accordance 
with our results [123, 128, 129, 207].  
Women suffering from BV do not display the same inflammation in the vulvovaginal tissue 
and have less pain and discomfort compared to women with acute candida infection. In 
pregnant women with BV, nitric oxide substrates in vaginal secretions is shown to be 
elevated [214]. Healthy postmenopausal women with higher vaginal pH did not have higher 
NO concentration than healthy premenopausal women, indicating that elevated NO levels are 
not dependent on the pH status but rather the abnormal microbial status of the mucosa [207].  
Fungal culture is the most precise method for diagnosing candida infection if wet mount is 
negative for hyphae. It is reported that visible yeast cells and hyphae are seen in 50% of 
patients with VVC [11]. Serologic tests and PCR-based diagnosis for antigen detection are 
currently not in clinical use, due to low reliability or too high sensitivity [12]. However, a 
positive culture alone does not necessarily prove that the yeast identified is responsible for the 
present vaginal symptoms, since 20 % of asymptomatic women are culture positive. A 
reliable diagnosis of vulvovaginal candidosis requires a combination of clinical findings, 
microscopic examination and vaginal culture that takes a few days to analyze [12].  
A majority of our patients had visible hyphae and positive cultures along with typical clinical 
findings. A correct diagnosis of recurrent infection needing treatment is important, but is 
sometimes difficult to obtain. Many RVVC patients continue to be symptomatic with itch and 
soreness after treatment, resulting in repeated gynecological examinations and most often 
excessive treatment with a potential risk of generating resistant candida strains. In that aspect 
vaginal NO measurement could serve as a complementary and instant diagnostic tool for 
recurrent infections with the intention to avoid unnecessary treatment. Based on our findings, 
using cut-off levels of either NO 25 or 50 ppb will ensure a low risk of prescribing 
fluconazole unnecessarily and only a few cases that could have benefitted from treatment will 
be missed, Figure 10 a. The ROC analyses showed that a careful examination in combination 
with microscopy also has a high sensitivity and specificity for a correct diagnosis confirmed 
by positive culture. However, the testing and examinations in this study was performed by a 
gynecologist with special training in vulvovaginal diseases and long experience of managing 
RVVC. In other less specialized clinical settings, NO measurements could be of value for 
diagnosing relapsing infections, even more so when a microscope is not available. In asthma 
and interstitial cystitis, NO analyses are used for monitoring the inflammatory activity and 
optimizing treatment [124, 134]. 
 
6.1.2 Psoriasin in C. albicans infections 
Several antimicrobial peptides with possible involvement in the mucosal immune response 
against candida were analyzed. The expression pattern was similar to a previously described 
expression survey of AMPs [189]. However, in that survey AMPs were analyzed in HPV 
positive vulvovaginal lesions inducing a different immune response in the mucosa compared 
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to candida infections. Psoriasin was the most up-regulated and expressed AMP during acute 
C. albicans infection. To find possible mechanistic actions of psoriasin, a pull-down assay 
was performed using whole C. albicans cells or the fungal cell wall elements, chitin, mannan 
and β-glucan. Psoriasin was found to bind to whole yeast cells and to β-glucan and was 
precipitated by C. albicans in the vaginal lavage samples.  
The antibacterial and antifungal activity by psoriasin is still not fully identified. Our 
experiments, performed in a solution resembling the vaginal milieu, indicate a strong 
interaction between psoriasin and β-glucan. Electron microscopic investigation showed 
significant thinning of the C. albicans cell wall with reduction of β-glucan after exposure to 
psoriasin, demonstrating a possible interaction with the protein. 
We studied two main phases in the pathogenesis of C. albicans infection. Adhesion and 
induction of cytokine response were investigated in order to examine possible consequences 
of psoriasin-mediated alterations of the candida cell wall. The experiment with vaginal lavage 
from patients with RVVC and healthy controls confirmed the presence of an anti-adhesive 
action. In an in vitro assay the anti-adhesive action was partially associated with psoriasin. 
However, in the lavage samples there was not a total blocking effect, indicating that 
additional anti-adhesins are present in vivo.  
After adhesion of a microbe, a receptor-mediated interaction with the host cell commonly 
induces an immune response in the tissue. Glucans, which are important fungal PAMPs, [35] 
bind to psoriasin. Since β-glucan has been shown to mediate induction of pro-inflammatory 
cytokines [36, 37], we anticipated a reduced immune stimulation as a consequence of the β-
glucan depleted cell wall of psoriasin treated candida cells. However, contrarily, in the in 
vitro experiments, the IL-8 production by vaginal epithelial cells was increased when C. 
albicans was pretreated with psoriasin. A possible explanation for this somewhat surprising 
result could be a reduction of the availability of soluble β-glucan in the cell wall since large 
β-glucan particles induce cytokine production, while soluble β-glucans act as antagonists of 
these processes [41]. We suggest that psoriasin might induce changes in the cell wall that 
amplifies exposure of large β-glucans at the cell surface. The mucosal immune protection 
against C. albicans might therefore be promoted by psoriasin mediated anti-adhesive effect 
and enhancement of cytokine expression. 
During an acute episode of RVVC, psoriasin was explicitly upregulated, although it did still 
not protect the host from infection. Since we only investigated patients with RVVC we 
cannot rule out that patients with a single acute infection with VVC trigger a psoriasin 
response that is more effective compared to patients with frequent infections. It is also 
interesting to speculate if polymorphisms in the psoriasin gene, S100A7, might be associated 
with recurrent candida infections. This remains an important field to explore in the future. 
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6.1.3 Antimicrobial peptides in HSIL 
Several mechanisms of immune evasion leading to the persistence of HPV infections have 
been described [10, 70, 71]. HPV do not replicate in antigen-presenting cells, do not cause 
lysis of keratinocytes and the infection does not cause a typical immune response with tissue 
damage. Thereby HPV avoid recognition by the immune cells. Despite the lack of typical 
immune response, HPV induce a persistent and chronic inflammation as the host can remain 
ignorant of the pathogen for long periods [10]. In the development of HPV associated 
neoplasia chronic inflammation plays an important role [180]. 
HIV infected women have higher incidence of HSIL and cervical cancer. Moreover, HPV 
infection may increase the risk to acquire HIV infection. One might speculate if HPV induce 
a local inflammatory response and thereby cause an impairment of the innate immunity, 
which could contribute to persistence of infection and thus promote HIV infection [195]. 
There are only a few studies addressing the role of AMPs and particular psoriasin in HPV 
induced precancerous and malignant lesions and the results from those studies are 
contradictory. Psoriasin is involved in the differentiation of keratinocytes and it promotes 
endothelial cell proliferation by increasing vascular endothelial growth factor (VEGF). 
Previous investigations on epithelial skin tumors have shown that precancerous lesions 
display higher expression of psoriasin compared to invasive tumors and healthy samples 
[191, 199]. Psoriasin expression is considered to correlate with tumor progression and is 
associated with poor prognosis in breast cancer and has been suggested as a candidate 
diagnostic marker [203, 205].  
We analyzed the expression of AMPs, with special focus on psoriasin, in cervical high-grade 
squamous intraepithelial lesions (HSIL) before and after surgical treatment. The performed 
analyzes were PCR, ELISA and IHC, thereby identifying both gene and protein expression in 
the same patients. Other studies in this field have mainly used one method at a time. 
Additional strengths in our study are the clearly defined and carefully selected study groups 
and two independent pathologists verifying the histopathological diagnosis.  
The results of our analyses in HSIL samples showed significantly lower expression of both 
mRNA and protein levels of psoriasin before treatment. After surgical excision the levels 
increased to equal levels as in healthy controls. The results diverge from results in previous 
investigations showing higher expression of psoriasin in precancerous lesions compared to 
controls [191, 199]. In benign vulvar condylomas, the expression of HBD-1-3 and psoriasin 
is significantly up-regulated [189]. During normal conditions in the oral mucosa, expression 
of psoriasin mRNA is higher than in extra-oral skin. Analyzing the protein levels showed 
contrasting results with a high quantity of protein retained in the keratinized epithelial layers 
[215]. The higher expression in the mucosa might be explained by the thinner mechanical 
barrier and multiple present microbes. The produced proteins may conduct their activity 
intracellularly or be released into the cavity. Our results indicate that psoriasin is 
downregulated in HPV induced HSIL which might be a part of the premalignant process, but 
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it can be discussed if the low levels rather are a prerequisite for persistent HPV. However, our 
study is small and lack samples from cervical cancer patients. There is need for larger studies 
to explain the role of AMPs in HPV induced pre- and malignant processes.   
IL-8 was analyzed to follow the inflammatory response. The mRNA expression was 
significantly higher in patients with HSIL before treatment compared to after treatment. 
Although, on the protein level, these results could not be confirmed. Since elevated levels of 
cytokines are proposed to affect the transformation of persistent infection to malignant 
lesions these results are in line with former results of elevated IL-8 in SCC and HSIL [195, 
199]. 
 
6.1.4  Biofilm and antifungal strategies 
Managing the treatment of RVVC is challenging. Many patients suffer from relapses despite 
adequate therapy and their quality of life is severely affected. C. albicans is the most common 
pathogen in RVVC and has a high capacity to form biofilm. Therefore, one can assume that 
biofilm is of importance for vaginal C. albicans creating an environment where the fungus 
can hide, persist and then disperse from the biofilm and cause recurrent infections. 
Consequently, it is important to find alternative treatment strategies to dissolve biofilm and 
expose the fungus to antifungals. It is also essential to find a way to prevent formation of 
biofilm. Our results show that both C. albicans from RVVC patients and commensal strains 
form biofilm. The commensal strains might have a potential to become pathogenic under 
other circumstances. 
The study analyzed the effect of fluconazole and chlorhexidine digluconate on biofilm from 
pathogenic and commensal strains. Since long-term administration of fluconazole is the first 
line treatment of RVVC [16], it is interesting to notice that our results show no effect of FLZ 
on preventing new biofilm formation nor any ability to dissolve already established biofilm. 
FLZ had the ability to reduce the planktonic candida cells but not candida growth within the 
biofilm, which is an important finding in the perspective of recurring infections.  
Several studies have shown antibacterial and antifungal effect of CHG [216, 217]. The 
proposed mechanism of action is interaction with the cell wall and the effects are dose 
dependent with both bacteriostatic and bactericide capacity [217]. Therefore, we investigated 
the effect of CHG alone and in combination with FLZ in C. albicans growth and impact on 
biofilm. 
CHG was able to dissolve established biofilm and treatment with CHG almost totally 
eradicated candida cells in the planktonic state. An essential finding was that CHG treatment 
also had effect on candida growth within the mature biofilm with a significant reduction of 
viable candida cells. We speculate that CHG might change the properties of the biofilm and 
thus enabling the molecules to penetrate and interact with the cell wall. 
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There was also a strong effect of CHG in inhibiting new biofilm formation which might be a 
key component of prevention and treatment of RVVC. If candida fails to produce biofilm the 
treatment and eradication of the pathogen will be manageable. 
We speculate whether women with RVVC are colonized with candida also between 
symptomatic episodes. If so, these strains need to be eradicated to avoid recurrences. Based 
on our results, vaginal CHG might be a possible treatment option for patients with RVVC and 
might also be prescribed for prophylactic use to diminish recurrences. In symptomatic cases a 
combined treatment with both CHG and FLZ could result in improved eradication of candida. 
It has previously been shown that chlorhexidine is superior to fluconazole in eradicating C. 
albicans in oral candidosis [218]. However, the influence on the commensal vaginal flora and 
the vaginal epithelial cells still needs to be clarified. 
 
6.2 METHODOLOGICAL CONSIDERATIONS 
6.2.1 Participants 
The patients were recruited from the Vulvar Clinic at Danderyd Hospital and from the 
national cervical screening program whereas the healthy controls were recruited through 
advertisements at Karolinska Institutet and Danderyd Hospital. A selection bias in Study I 
and II must be considered since the controls were significantly younger than the patients and 
the majority of the healthy controls were university students. However, a majority of the 
patients also had a high level of education.  
Considerable effort was done to carefully exclude patients and controls with concomitant 
genital infections since other mucosal infections might have influenced the results in several 
aspects. The exclusion criteria were strictly followed. Fifty-eight women with assumptive 
candida infection came for a recruitment visit, but only 28 subjects fulfilled the inclusion 
criteria for study I, Figure 7. Due to methodological reasons, we could only include 16 of the 
patients in Study II and 18 patients in study IV. Of the 37 invited patients with cervical 
dysplasia, 19 patients were included, Figure 8. The meticulous sampling and the inclusion 
process are major strengths of the studies. However, one must consider the deficient selection 
of participants to study II and IV as weakness of the studies.  
Another limitation of the studies is the shortage of menstrual data. However, it has been 
shown that NO levels show no significant variation during the menstrual cycle [129]. It has 
been described that some AMPs vary during the menstrual cycle but the cyclic regulation is 
abolished in oral contraceptive and levonorgestrel intrauterine device users [168]. Another 
weakness of Study III is the lack of samples from patients with cervical cancer which would 
have added valuable information in elucidating the role of AMPs in HPV induced 
premalignant and malignant lesions. The low number of samples is a major limitation of 
Study III and IV and the in vitro results need to be confirmed in clinical trials. 
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6.2.2 NO measurement 
NO has previously been shown to be an indicator of inflammation in disorders of various 
organs. The method for NO measurement in the vagina, using the catheter balloon, was first 
described by Sioutas et al [207]. The method was also evaluated in the uterine cavity by the 
same group [208], showing that 2 min incubation of the balloon is a sufficient time to 
measure the NO levels. The procedure was well tolerated and had no complications.  
We chose to use the chemiluminescence analysis, which is a direct method measuring the 
actual NO concentration. Babula et al, showed that women with RVVC, during an episode of 
acute culture-verified infection had lower concentrations of the NO metabolites nitrite and 
nitrate compared to controls, as opposed to our results [219]. Measuring NO metabolites is an 
indirect method and these markers in vaginal fluid are influenced by several other factors 
such as dietary discrepancies and the presence of commensal bacteria [220]. Since bacteria 
can both produce and consume nitrate and nitrite they might affect the outcome based on 
analyses of these substances [221].  
 
6.2.3 Examination and sampling 
Methodological aspects on the testing procedures should be considered. The methods with 
examination and symptom scores were designed for Study I. The scores have not previously 
been used and are not validated. To minimize detection bias in the examination score, the 
same examiner did all the scoring. Since the RVVC patients had a long history of symptoms 
one might consider recall bias. 
Four patients had positive culture for C. albicans after antifungal therapy and five other 
patients had visible hyphae in wet mount. Culture is considered the most reliable method to 
identify candida infection [16] and the divergence in results of the two methods could be 
caused by an over diagnosis of hyphae in the microscope or a misdiagnose of fungal culture. 
Positive culture for C. albicans and symptoms of vulvovaginal candidiasis were inclusion 
criterion, which minimize selection bias. 
The sampling of vaginal lavage for Study II was technically challenging and in some cases it 
was not possible to obtain any VL after the installation time of 5 minutes, because the fluid 
did not remain in the vagina. This was the major reason why only 16 patients were included 
in Study II.  
The samples taken from the vaginal wall for Study I and II were on the other hand easy to 
obtain. The tissue was injected with local anesthetic and the sampling was well tolerated. The 
general mucosal inflammation seen in VVC implies that the biopsy samples are 
representative for inflammatory changes throughout the vagina. The representation of the 
samples taken from the cervix in Study III was more complicated. The samples were obtained 
after colposcopic identification of the suspected lesions. However, it can be technically 
difficult to acquire several samples from the same area of HSIL. The representation of the 
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samples does probably not reflect the total picture of AMPs throughout the whole cervical 
mucosa. The follow-up biopsies were taken from the transformation zone of the cervix. 
Since the commensal strains in Study IV were randomly selected we do not have any data of 
the women harboring these strains and one might consider selection bias.  
 
6.2.4 Treatment 
The RVVC patients received antifungal therapy with oral fluconazole for six weeks for study 
purposes and in accordance with Swedish guidelines at the time of the study. After treatment, 
four patients had positive cultures which is in line with the pathogenesis of RVVC with high 
recurrence rate of the infections. The length of the treatment period might have been too short 
to eliminate growth of C. albicans in all patients, alternatively the fluconazole dose was too 
low. These results demonstrate that long-term treatment is needed as previously presented 
and that the dose needs to be individualized. The recommended long-term treatment is 
fluconazole, with induction of 150 mg every 72 h for 3 doses and thereafter maintenance 
regimen with 150 mg weekly for 6 months [16].  
If the candida species are resistant to fluconazole the treatment has to be adapted to the 
susceptibility test results. Oral treatment with itraconazole or local treatment with 
clotrimazol, econazole or boric acid can be used. Local steroids in combination with anti-
fungal treatment is sometimes used during acute infection to relive symptoms of the vulva.  
 
6.2.5 Chemicals and reagents 
Vaginal fluid simulant was used as a medium to mimic the vaginal milieu. Original vaginal 
secretion includes fluid from the upper reproductive tract such as endometrial and tubal 
fluids, cervical mucus, vaginal transudate and exfoliated epithelial cells. The VFS used in our 
study is intended to have the same properties as the secretion originating in the vagina of non-
pregnant, premenopausal and healthy women. The formulation of VFS has been proved 
useful in other research of contraceptive and drug administration [212]. 
Chlorhexidine digluconate as an antiseptic for vaginal use has only been limitedly explored 
[222]. Since CHG has a broad effect on microbes one must consider the influence on the 
commensal bacterial flora. Al-Niaimi et al showed that use of 2% chlorhexidine gluconate as 
vaginal preoperative preparation was not associated with increased vaginal irritation or 
allergic reactions [223]. When treating women with intravaginal 0.5% chlorhexidine 
gluconate gel for 7 days the tolerability was good [222]. 
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6.3 FUTURE PERSPECTIVES AND CLINICAL IMPLICATIONS  
Vaginitis is amongst the most common clinical problems in women of childbearing age, 
annually accounting for millions of gynecological office visits worldwide. RVVC causes 
excessive suffering and affect the patients’ sexual health and quality of life. Moreover, 
RVVC is a known risk factor for development of vulvar pain and dyspareunia and it is 
suggested that the repeated inflammation induces hypersensitivity and hyperinnervation of 
the vulvovaginal mucosa. A possible reduction of the inflammatory response during RVVC 
might be of great importance to decrease that risk. In treatment of other chronic inflammatory 
conditions such as asthma, reduction of inflammation has priority over cure. Accordingly, 
complementary treatment to reduce the inflammatory tissue response in patients with RVVC 
might be of value. Since a correct diagnosis of RVVC can be difficult to obtain, NO 
measurement might be a useful complementary diagnostic tool, in some settings. Over 
consumption of fluconazole, which might lead to antifungal resistance in the long term could 
thus be avoided.  It would be of interest to study NO levels in other gynecological conditions 
with affected immune response, such as BV. BV often coexist with candida and although it 
does not cause visible inflammation in the vaginal mucosa some symptoms overlap with 
candida vulvovaginitis.  
There is great need for new treatment options and prevention strategies for vulvovaginal 
candida infections. Recurrences are a major clinical difficulty and there is a lack of useful 
prophylactic approaches. Since biofilm is a major part of candida virulence, new approaches 
in antifungal therapies focusing on biofilm eradication would be valuable. As long as the 
antifungal treatment does not affect the candida cells in the biofilm, possibility of resolving 
the infection is low. Treatment aiming to dissolve biofilm and kill the candida cells within the 
biofilm would be an ideal approach. Our results indicate such an action by chlorhexidine 
digluconate. CHG is easy to obtain, inexpensive and formulations for vaginal use have 
previously been described. However, to evaluate and compare the effect with other antifungal 
preparations, randomized, blinded treatment studies have to be conducted. It would also be of 
great interest to analyze the effect of CHG-fluconazole combination treatment and to evaluate 
possible prophylactic effects. Also, it is essential to ensure there are no harmful effects on the 
normal vaginal flora which has a key function for vaginal health. The effect on vaginal 
epithelial cells needs to be investigated to identify potential unwanted side effects. 
Furthermore it still remains for future research to further reveal the pathogenesis of RVVC 
and identify additional mechanisms leading to candida persistence, which is a mechanism for 
cells to hide from immune cells and antifungal treatment. 
Moreover the mechanisms of AMPs in inflammatory response and carcinogenesis need to be 
further explored both in animal models and humans before the results can be applied 
clinically. Psoriasin has been shown to take part in the immune response and have multiple 
functions. It may be beneficial for the host but contradictory it might also be involved in 
tumor progression.  Psoriasin has been suggested as part of a panel of clinical biomarkers, 
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aimed at diagnostics and mapping of epithelial malignant conditions such as breast and 
bladder cancer. 
Finding a possible clinical use for antimicrobial peptides against skin and mucosal infections 
is a future possibility. Synthetic and non-toxic topical formulas of AMPs as treatment or 
prevention of infections could be an interesting prospect. However, more knowledge is 
needed in this field since synthetic AMP derivatives previously designed have shown 
cytotoxicity such as hemolysis. The probability of unintended leakage into systemic 
circulation must be considered as well as the risk of potentiating the neoplastic development, 
since continuous presence of AMPs might trigger the inflammatory process.  
The results of this thesis emphasize that the innate immune system plays as an important role 
in recurrent gynecological infections. If targets of innate immunity are found, they might be 
possible objectives for future treatment, as an alternative to current pharmacological 
antimicrobial treatment. Future discoveries of possibilities to strengthen the local immune 
defense to prevent microbes from invading tissues would also be of great importance.  
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7 CONCLUSIONS 
Innate immune response is induced by RVVC and HPV infections of the lower female genital 
tract. A better understanding of local innate immunity is important to enable development of 
future preventive and therapeutic strategies for these infections. 
 
 NO is significantly elevated in patients with acute episodes of RVVC and decreases 
after antifungal treatment. Results illustrate that the pronounced inflammatory 
response in the tissue during infection correlates to the patients´symptoms. iNOS 
expression in the mucosa suggest that NO is produced by epithelial cells. 
 
 A novel mechanistic action of psoriasin was identified, demonstrating that psoriasin 
has an anti-adhesive effect on C. albicans. Further, psoriasin affects the 
proinflammatory response in the epithelial cells. 
 
 In HPV induced cervical highgrade squamous intraepithelial lesions, the gene 
expression and protein levels of the antimicrobial peptide psoriasin were lower before 
treatment. Six months post conisation, levels were elevated and comparable to those 
in healthy controls with a corresponding reduction of IL-8 mRNA expression.  
 
 Chlorhexidine digluconate inhibits biofilm formation and dissolves already 
established, mature, biofilm. In addition, chlorhexidine digluconate eradicates C. 
albicans both in planktonic phase and within biofilm. Although fluconazole is 
effective against planktonic C. albicans, it has no effect on biofilm or candida cells 
within the biofilm.  
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Faktorer i det lokala immunförsvaret som påverkas vid upprepade och 
kvarstående gynekologiska infektioner 
Bakgrund  
Gynekologiska infektioner är mycket vanliga och orsakas av olika bakterier, virus, svampar 
och parasiter. Vissa kan ge långdragna och återkommande besvär som i många fall leder till 
stort lidande, försämrad sexualitet och sänkt livskvalitet. De vanligaste symtomen är 
flytningar, rodnad, klåda, smärta, blödning och samlagssmärta. Merparten av infektionerna, 
men inte alla, är sexuellt överförbara. Sjuttiofem procent av alla kvinnor får svampinfektion 
någon gång i livet och 6-9% drabbas av återkommande svampinfektioner (RVVC), definierat 
som 3-4 infektioner/år. Dessa kvinnor är oftast helt friska i övrigt och orsakerna till de 
återkommande infektionerna är oklara och anses multifaktoriella. RVVC är i regel 
svårbehandlat och medför ofta konstanta lokala besvär hos kvinnan. Vid upprepade 
infektioner finns det en ökad risk för utveckling av vestibulodyni, ett smärttillstånd runt 
slidöppningen som i många fall omöjliggör samlag.  
Humant papillomvirus (HPV) är den vanligaste sexuellt överförda infektionen i världen och 
majoriteten av dessa infektioner läker ut spontant. Det finns över 200 varianter av HPV som 
delas in i låg- och högrisk typ med avseende på deras förmåga att inducera cellförändringar 
och cancerutveckling. Kvarstående HPV infektion kan orsaka cancer i livmoderhalsen, 
vagina, vulva, analkanalen, penis, mun och svalg. Livmodertappens yta är särskilt känslig för 
infektionen. I transformationszonen där två olika typer av slemhinnor möts, finns det stor risk 
att virusgenomet inkorporeras i värdcellens DNA. Cellförändringarna delas in i olika grader 
och förändringarna kan upptäckas i tidigt skede med den screeningverksamhet med 
cellprovtagning som finns i många länder. I och med genomförandet av screening i Sverige, 
har antalet fall av livmoderhalscancer minskat betydligt.  
Orsakerna till varför en del infektioner inte läker ut eller återkommer gång på gång hos vissa 
individer är oklara. Man har hittills inte kunnat hitta någon säker förklaring varken i det 
medfödda eller i det specifika immunförsvaret. Det medfödda lokala immunförsvaret är 
komplext och består av många olika komponenter som har stor betydelse för infektionernas 
läkningsprocess. Kvävemonoxid (nitric oxide (NO)), antimikrobiella peptider (AMP) och 
cytokiner är alla viktiga faktorer i det medfödda immunförsvaret som riktas mot invaderande 
mikroorganismer. Det saknas idag fortfarande mycket kunskap om hur dessa komponenter 
påverkar den inflammatoriska processen vid infektioner och hur kopplingen till 
cancerutveckling ser ut. 
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Målsättningar 
Våra huvudmålsättningar var att undersöka NO, AMP och cytokiner hos kvinnor med 
upprepade vulvovaginala svampinfektioner och i HPV inducerade precancerösa förändringar 
på livmodertappen med syfte att öka förståelsen av det medfödda immunförsvarets roll vid 
dessa infektioner. 
 
Specifika målsättningar 
 Att mäta NO koncentrationen i vagina samt att studera uttrycket av enzymet iNOS i 
vaginala biopsier före och efter behandling av en akut episod av återkommande 
vulvovaginal candidainfektion och att jämföra med friska kontroller. Att korrelera NO 
koncentrationen till symtom och till den kliniska bilden. 
 
 Att undersöka interaktionen mellan svampen C. albicans och det lokala försvaret i 
vaginas slemhinna, med avseende på anitmikrobiella peptider vid RVVC och att 
förstå den antimikrobiella peptiden psoriasins roll i slemhinnans försvar mot C. 
albicans. 
 
 Att studera uttrycket av antimikrobiella peptider och cytokinet IL-8 i vävnad hos 
patienter med precancerösa förändringar på livmodertappen före och efter behandling 
och jämföra med friska kontroller. 
 
 Att undersöka effekten av klorhexidindiglukonat på C. albicans och dess biofilm från 
patienter med RVVC och att jämföra effekten med flukonazol, den vanligaste 
behandlingen vid RVVC. 
 
Material och Metoder 
I studierna ingick 28 patienter med RVVC, 19 patienter med höggradiga cellförändringar på 
livmodertappen och 45 friska kontroller. Alla deltagare genomgick en noggrann 
undersökning för att utesluta andra infektioner som skulle kunna påverka resultaten. Hos 
patienterna med svampinfektion mättes NO koncentrationen i vagina före och efter 
behandling och vävnadsprover togs från slemhinnan i vagina. Dessa jämfördes med prover 
från friska kontroller. I vävnadsproverna analyserades förekomst och mängd av 
antimikrobiella peptider samt förekomsten av enzymet iNOS som styr bildandet och 
frisättningen av NO. Peptiden psoriasin visade sig intressant och vi studerade dess funktion i 
det lokala försvaret mot C. albicans med ett flertal olika analysmetoder.  
Patienterna med cellförändringar genomgick provtagning av livmodertappen och kirurgisk 
behandling. I vävnadsprover analyserades förekomst och mängd av antimikrobiella peptider 
på samma sätt som hos patienterna med svamp. 
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Behandlingseffekten av klorhexidindiglukonat och flukonazol studerades hos C. albicans 
stammar från patienter med upprepade infektioner samt stammar från symtomfria kvinnor. 
Effekten avseende nybildning av biofilm, förmåga att bryta ner etablerad biofilm och 
avdödande av candida celler studerades. 
 
Resultat  
NO i vagina har en kraftigt förhöjd koncentration hos patienter med en akut episod av RVVC. 
Efter behandling sjunker koncentrationen betydligt men kommer fortfarande inte ner i samma 
låga nivå som hos friska kontroller. NO koncentrationen korrelerar väl till graden av symtom 
och kliniska fynd. iNOS kunde identifieras i epitelcellslagret i högre andel av patienterna 
jämfört med de friska kontrollerna. 
Den antimikrobiella peptiden psoriasin ökar signifikant vid infektion med C. albicans. 
Psoriasin binder till β-glucan som är en beståndsdel i cellväggen hos C. albicans. Där 
påverkar den cellväggens tjocklek och minskar svampens vidhäftningsförmåga till vävnaden. 
Psoriasin tillsammans med C. albicans påverkar det proinflammatoriska svaret i epitelet. 
Proteinkoncentrationen och gen uttrycket av den antimikrobiella peptiden psoriasin hos 
patienter med HPV inducerade precancerösa cellförändringar var låga före behandling och 
ökade signifikant sex månader efter kirurgisk behandling. Samtidigt sågs en minskning av 
genuttrycket av den proinflammatoriska cytokinen IL-8 efter behandling. Analys av 
proteinnivåerna kunde dock inte verifiera denna skillnad relaterad till behandling. 
I våra cellstudier har klorhexidindiglukonat god effekt mot C. albicans och dess biofilm. Vi 
visar att substansen påverkar både nedbrytning och nybildande av biofilm. Klorhexidin-
diglukonat är dessutom mer effektiv än flukonazol, den rekommenderade behandlingen vid 
RVVC, på att avdöda candida celler som finns inne i biofilmen.  
 
Slutsats  
Resultaten visar att det medfödda immunförsvaret spelar en viktig roll vid RVVC och vid 
HPV inducerade cellförändringar på livmodertappen. NO nivåer speglar det inflammatoriska 
svaret i vävnaden vid akuta episoder av RVVC och korrelerar väl till den kliniska bilden och 
patientens symtom. Våra resultat visar en ny funktion hos den antimikrobiella peptiden 
psoriasin som motverkar att candida fäster till vävnaden och på så sätt försvårar utvecklingen 
av infektionen.  
Det finns ett stort behov av nya strategier för preventiva åtgärder och behandlingsmetoder vid 
RVVC. De behandlingar som finns idag är inte alltid effektiva och många patienter får täta 
återfall när behandlingen avslutas. I våra analyser visar vi att klorhexidindiglukonat kan vara 
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ett alternativ för att förbygga och behandla infektioner med C. albicans, men resultaten 
behöver bekräftas i kliniska behandlingsstudier.   
Psoriasin koncentrationerna och det proinflammatoriska svaret i vävnaden påverkas även vid 
HPV inducerade precancerösa förändringar på livmodertappen. Betydelsen av detta fynd är 
fortfarande oklar, men tidigare studier av andra cancerformer har visat att det finns samband 
mellan psoriasin och utveckling av viss cancer. Framtida forskning behöver fortsätta 
undersöka antimikrobiella peptiders roll vid den maligna processen där psoriasin eventuellt 
kan fungera som markör och prognostisk faktor.  
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